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Common eye diseases such as conjunctivitis affect around 6 million people annually. Although 
eye drops are the most common treatment for these diseases, topical administration is limited by low 
ocular bioavailability due to lachrymal drainage, low drug permeability across the corneal epithelium, and 
low drug stability as a result of tear dilution and turnover. This results in over 95% of the drugs applied 
through eye drops to be quickly cleared away. Consequently, patients struggle with the multiple daily 
applications required and the resulting side effects. 
In order to overcome these barriers and to increase contact time of drugs on the surface of the 
eye, several nanoparticle (NP) technologies have been developed for the delivery of drugs to our systems 
like liposomes, hydrogels, microparticles, micelles, implants...etc. NP surfaces can be tuned to achieve 
specific properties such as binding affinity towards the ocular surface. NPs can also carry a large amount 
of drugs and release them in a sustained manner over a long period. Due to their small size, NPs do not 
cause abrasive sensations on the eye upon patient application. There is no one technology that is suitable 
for any drug to any site, however biodegradable colloidal systems appear to be the most advantageous. 
Their popularity stems from their biocompatibility with ocular tissues, high encapsulation efficiency, 
sustained release, and ability to degrade into non-toxic by-products that are safely cleared from ocular 
tissues. With these unique advantages, NP drug carriers may drastically improve patient compliance while 
reducing side effects. 
Research conducted in the Frank Gu Research Group suggests that NP drug carriers are capable 
of circumventing corneal clearance mechanisms by manipulating the surface functionalization of 
polymeric nanoparticles (NPs) such that they can interact with the ocular mucosa. In view of this 
background, this thesis was aimed at exploring the potential of mucoadhesive NPs (MNPs) to encapsulate 
hydrophilic drugs in the core of the NP, while maintaining mucoadhesive functionality in the shell of the 
NP. We developed a novel approach to formulate a double emulsion mucoadhesive nanoparticle (DE 
MNP) system to deliver hydrophilic molecules.  
Double emulsions allow us to generate a vesicle-like structure of hydrophilic interior and 
hydrophilic exterior and have been successful as nanoparticle drug carriers in the past. Most double 
emulsions utilize PLGA to make up the primary emulsion because it is a biodegradable and biocompatible 
polymer that has the ability to degrade into non-toxic by-products (lactic acid and glycolic acid) that are 
metabolized by the human body. The novelty in the DE MNP method involves using PLA-Dex-PBA in 
the outer emulsion, rather than common stabilizers such as PVA and Tween. The amphiphilic 
characteristics of PLA-Dex-PBA will arrange on the surface of PLGA emulsions with PLA facing the oil 




moieties on the surface of DE MNPs can covalently target the sialic acid moieties that are abundant on 
the ocular mucous membrane and avoid rapid clearance. DE MNPs form the foundation of the ocular 
drug delivery platform developed in this thesis, using fluorescein isothiocyanate dextran (FITC-Dex), a 
commercially used fluorescent dye, as the model drug to determine the capability of DE MNPs to 
encapsulate and release hydrophilic molecules. DE MNPs were first evaluated for size and morphology. 
They demonstrated sizes in the sub-200 nm range, nearly double the size of PLA-Dex-PBA MNP micelles. 
Their spherical shell/vesicle conformation was confirmed by static light scattering and TEM, and remained 
stable and unchanged with the addition of model FITC-Dex. DE MNPs demonstrated encapsulation of 
FITC-Dex up to 87 wt%, and sustained release for up to 7 days in vitro, showing their potential as a long-
term eye drop delivery platform. 
In vitro mucoadhesion study as a proof of concept demonstration of PBA on DE MNPs’ surfaces 
was demonstrated by studying the binding kinetics of PBA to sialic acid through the Stern-Volmer 
equation. The KA value for DE MNPs with sialic acid was determined to be 107.83 M-1, which is far 
higher than the literature values for PBA-SA. This gave confidence to the presence of PBA on the surface 
of DE MNPs. Next, we proceeded to attempt to demonstrate this mucoadhesion using in vivo models. 
FITC-Dex was encapsulated in the NPs and administered to rabbit eyes to track its ocular retention. 
FITC-Dex delivered DE MNPs showed ocular retention for no longer than 3 hours on rabbit eyes; this 
trend was also seen for free FITC-Dex.  
Povidone-Iodine (PVP-I), an inexpensive and commercially available drug commonly used to 
treat ocular bacterial infections, was encapsulated and evaluated for bactericidal activity upon release from 
DE MNPs. DE MNPs revealed that that encapsulation of the drug did not change the properties of the 
drug, and also confirmed that the amount of drug being encapsulated (1% w/v) in DE MNPs, is a sufficient 
concentration to elicit antimicrobial activity, and better than current formulations such as Betadine® 
which uses 5%w/v PVP-I for treatment of ocular infection.  
This thesis demonstrates the development process of DE MNPs as topical ocular drug delivery 
systems for hydrophilic drugs. DE MNPs demonstrated delivery of a clinically relevant dosage of PVP-I, 
controlled release of therapeutics over prolonged period of time, and mucoadhesive properties in 
vitro. These DE mucoadhesive NPs show significant promise as a long-term topical ocular hydrophilic 
drug delivery system that significantly reduces the dose and the administration frequency of the eye drops 
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Ocular drug delivery remains among the most challenging approaches to administering therapeutic agents 
due to the complexity of the physiological environments surrounding the eye. The eye has many 
mechanisms in place to protect it from both its external and internal environments [6] and drug delivery 
to this sensitive and sophisticated organ can be challenging since the eye's protective barriers need to be 
circumvented if one is to establish therapeutically effective drug concentrations in the intraocular tissues 
[7]. These barriers come in the form of physiochemical limitations of the biopharmaceuticals 
themselves, the physiology and anatomy of the eye, and the formulation conditions of the carriers for 
these protein therapeutics.  
Topical administration in the form of ophthalmic drops is the most popular and preferred route 
to treat anterior segment diseases due to its non- invasiveness and ease of application. However, the 
efficiency of topical drug administration is limited by low ocular bioavailability due to rapid drainage, 
low drug permeability across the corneal epithelium, and low drug stability as a result of tear dilution 
and turnover; as a result, approximately 95% of the administered drugs are cleared within ten minutes 
of administration [6]. Therefore, topical formulations typically require frequent administration, which 
increases the risk of side effects, and leads to lower patient compliance. 
  Nanocarrier-based ocular drug delivery systems appear to be the most promising tool for 
targeted drug delivery. The use of nanoparticles (NPs) as drug carriers represents a significant 
improvement over traditional oral and intravenous methods of administration. It protects drugs from 
degradation and reduces the dosage of the drug administered, thus improving drug efficacy and 
efficiency in addition to limiting unwanted side effects [7]. Furthermore, NP drug carriers have the 
potential to overcome challenges posed by current eye drop formulations. These carriers have high 
surface area-to-volume ratios due to their small size, which provide an optimal template for targeted 
drug delivery and improves patient comfort because it is non-abrasive on the surface of the eye. NP drug 
carriers have already demonstrated high diffusivity across membranes such as the corneal epithelium 
due to their small size [2], and they have been found to improve the stability of drugs through 




Currently, a variety of NP drug delivery platforms have been investigated including, but not limited to, 
liposomes, micelles, nanospheres, nanocapsules, polymerosomes, and carbon nanotubes. 
Research conducted in the Frank Gu Research Group suggests that NP drug carriers are capable 
of circumventing corneal clearance mechanisms by manipulating the surface functionalization of 
polymeric NPs such that they can interact with the ocular mucosa [2].  
 
Figure 1.1 Schematic of MNPs with hydrophobic PLA, hydrophilic dextran, and surface-
functionalized PBA grafts. 
The Frank Gu Research Group has developed mucoadhesive nanoparticles (MNPs) for targeted drug 
delivery to the ocular surface. The presence of a mucus layer in the anterior segment of the eye allows 
MNPs to prolong the retention of the topically administered drug formulations by binding to sialic acid 
- an abundant terminal sugar on the mucus membrane of the eye. These MNPs are polymeric self-
assembled micelles that contain a hydrophobic core of poly(lactic acid) (PLA), a hydrophilic shell of 
dextran, and phenylboronic acid (PBA) grafted onto the dextran as illustrated in Figure 1.  
Previous research suggests that MNPs improve the stability of drugs through encapsulation, and 
prolong the desired therapeutic effects of encapsulated drugs by releasing them in a controlled manner 
over a period of five days [8]. This platform, however, is only suitable for encapsulation and delivery of 
hydrophobic drugs such as Cyclosporine A (CsA) and used to treat dry-eye disease. If this is to be 
implemented to treat adenoviral conjunctivitis, it must adapt to a hydrophilic system since most of the 
current treatments involve hydrophilic compounds.  
  This thesis aims to manipulate the MNP platform to generate a drug delivery system capable of 
enhancing hydrophilic drug efficacy of topical formulations targeting anterior segments of the eye. A 




encapsulate hydrophilic drugs in the core of the NPs, while maintaining mucoadhesive functionality in 
the shell of the NP.  
The surfaces of these DE MNPs exhibited phenylboronic acid (PBA) moieties, which can 
covalently target the sialic acid moieties that are abundant on the ocular mucous membrane. These DE 
MNPs were evaluated for size and morphology. Fluorescein isothiocyanate dextran (FITC-Dex), a 
commercially used fluorescent dye, was used as a model drug to determine the capability of DE MNPs to 
encapsulate and release hydrophilic molecules. Povidone-Iodine (PVP-I), a commercially available drug 
commonly used to treat adenoviral conjunctivitis, was encapsulated and evaluated for bactericidal 
activity upon release from DE MNPs.  Finally, animal studies were used to evaluate the mucoadhesive 
properties of DE MNPs and calculate their ocular retention time. 
 
1.2 Research objectives  
The overall objective of the proposed project is to evolve an established mucoadhesive nanoparticle 
drug delivery system developed by the Frank Gu Research Group, capable of enhancing therapeutic 
efficacy of hydrophobic topical formulations targeting anterior segments of the eye, to include 
hydrophilic drug molecules. We hypothesize that double emulsion mucoadhesive NPs would enhance 
topical delivery of hydrophilic drugs by improving their specific targeting and prolonged retention in 
the eye. By providing controlled drug release, DE MNPs would improve the bioavailability of 
hydrophilic drugs in the eye, requiring reduced frequency of administration and resulting in improved 
therapeutic efficacy. The specific objectives of the study are as follows: 
1. Establish biodegradable polymers that are commonly used to prepare water-in-oil-in-water 
(W/O/W) double emulsions capable of encapsulating and controlling the release of therapeutics. 
2. Synthesize double emulsion nanoparticles, through use of biodegradable polymers and PLA-
Dex-PBA 
3. Characterize the size, morphology, drug encapsulation, and drug delivery capacity of the 
nanoparticles formed using FITC-Dex as a model drug 
a. Demonstrate mucoadhesion properties of DE MNPs 
b. Demonstrate the prolonged ocular retention of DE MNPs on the ocular surface of rabbits 
4. Test the application of DE MNPs for topical ocular delivery using PVP-I 




1.3 Thesis outline 
This thesis is comprised of 6 chapters: the introduction, a literature review, three experimental research-
based chapters, and a final chapter featuring the conclusion and recommended future work.  
Chapter 1 introduces the key challenges that will addressed in the thesis, the hypothesis and research 
objectives to test this hypothesis.  
Chapter 2 reviews the current status of using nanoparticles for hydrophilic drug delivery using 
biodegradable polymers. 
Chapter 3 describes the methods behind the synthesis of DE MNPs, and the in vitro and in vivo 
characterization of the nanoparticles formed from the solvent evaporation process. This chapter focuses 
on the efficacy of DE MNPs as hydrophilic drug carriers using a using a fluorescent dye (FITC-Dex) as 
the model drug.  
Chapter 4 presents the methods of evaluating the mucoadhesive capabilities of DE MNPs both in vitro 
and in vivo. This chapter focuses on the specific targeting of DE MNPs to sialic acid on the mucus 
membrane of the anterior surface of the eye and the ability of DE MNPs to prolong retention of 
hydrophilic drug carriers, using a fluorescent dye (FITC-Dex) as the model drug.  
Chapter 5 describes the methods of determining the feasibility of DE MNPs to encapsulate hydrophilic 
antimicrobial agents and exhibit bactericidal activity in vitro when released from DE MNPs. This chapter 
focuses on the efficacy of DE MNPs as hydrophilic drug carriers using a using polyvinylpyrrolidone-
iodine (PVP-I) as the antimicrobial drug. 
Chapter 6 highlights the conclusions drawn from the research described in chapters 3, 4, and 5, and 








2.1 Introduction: Hydrophilic Ocular Drug Delivery 
Ocular drug delivery remains among the most challenging approaches to administering therapeutic agents 
because a successful therapeutic treatment requires circumventing both anatomical and physiological 
barriers in order to preserve the therapeutic drug concentration at the target site. These barriers come in 
the form of physiochemical limitations of the biopharmaceuticals themselves, the physiology and 
anatomy of the anterior and posterior segments of the eye, and the formulation conditions of the carriers 
for therapeutic agents. Furthermore, many drugs need to pass through one or more cell membranes to 
reach their site of action [9]. This is not a problem for small hydrophobic drugs, however for larger 
hydrophilic drugs, penetrating biological membranes is challenging, resulting in reduced therapeutic 
efficacy due to low permeability and bioavailability [10].  
The main routes of administration of biopharmaceuticals include topical, periocular, 
suprachoroidal, and intravitreal. Topical administration in the form of ophthalmic drops is the most 
popular and preferred route to treat anterior segment diseases due to its non- invasiveness and ease of 
application. However, it is very difficult to achieve therapeutic drug concentrations by this method 
because of precorneal factors such as blinking, nasolacrimal drainage, and transient residence time in the 
cul- de-sac [1]. Furthermore, the lipoidal nature of the corneal epithelium restricts the entry of hydrophilic 
drug molecules and as a result, topically applied drugs have an ocular bioavailability of less than 5% [11]. 
For these reasons, there is a need to develop novel ophthalmic biopharmaceutical drugs and delivery 
systems, ideally targeting these macromolecules to biologically relevant ocular tissues [1]. 
In order to overcome these barriers and to increase contact time of drugs on the surface of the 
eye, several technologies have been developed for the delivery of drugs to our systems like liposomes, 
hydrogels, microparticles, micelles, implants...etc. There is no one technology that is suitable for any 
drug to any site, however biodegradable colloidal systems appear to be the most advantageous. Their 
popularity stems from their biocompatibility with ocular tissues, high encapsulation efficiency, sustained 
release, and ability to degrade into non-toxic by-products that are safely cleared from ocular tissues [12]. 
Natural and synthetic biodegradable polymers have been thoroughly explored and approved by the FDA 




This review aims to examine the challenges surrounding successful hydrophilic drug delivery to 
ocular tissues, exploring various biodegradable drug delivery systems designed for human ophthalmic 
disease therapy.  
 
2.2 Challenges in Hydrophilic Drug Delivery 
 
2.2.1 Physiochemical Properties of Hydrophilic Drugs 
Bioavailability of hydrophilic drugs depends largely on their ability to cross biological cell membranes 
as they possess intracellular target sites [13]. The lipophilic nature of biological membranes acts as a 
major barrier for hydrophilic drugs as it impedes their entry into cells. Additionally, the presence of 
tight junctions in the cornea, sclera, and retina, and the lipophilic nature of the corneal epithelium, hinders 
the permeation of these hydrophilic therapeutics [14]. Many of these large and hydrophilic drugs come 
in the form of protein and peptide pharmaceuticals which have gained a lot of popularity in the last 
decade due to their advantages over conventional small molecule drugs with respect to high potency, 
activity, low unspecific binding, less toxicity, and minimal drug-drug interaction [10]. Conventional 
molecules are typically low molecular weight, reasonably lipophilic and hence are quite stable and can 
be transported satisfactorily across cellular barriers into the blood and to their sites of action. They do 
not require sophisticated delivery systems unlike proteins which are unstable, high molecular weight, 
hydrophilic, complicated in structure, larger in size, and less permeable. As a result, they are harder to 
deliver by conventional ways. Additionally, the processes involved in the fabrication of drug delivery 
systems may inactivate the drugs in a number of ways including, but not limited to aggregation, 
denaturation, or chemical degradation [10]. Therefore, maintaining the structural integrity of hydrophilic 
drugs through all formulation steps of generating a delivery system is essential for its successful 
delivery. In addition, possible bioactivity loss and low stability of biopharmaceuticals due to interactions 
with the nanoparticle matrix, and extensive nanoencapsulation methods may further complicate the 
success of hydrophilic drug delivery.   
 
2.2.2 Barriers due to Ocular Anatomy 
The efficiency with which drugs are successfully delivered has largely been limited by the presence of 
ocular barriers. The human eye consists of two main components, the anterior surface which consists of 
the cornea, the conjunctiva, and the sclera [7], and the posterior surface which consists of the choroid 




Upon the addition of biopharmaceuticals, there are several corneal factors and anatomical 
barriers that come into play and negatively affect the bioavailability of these formulations. Precorneal 
factors include solution drainage, blinking, tear film, tear turnover, and induced lacrimation [15]. The 
first point of resistance is the tear film. Tear film has a high turnover rate of 16%/min of the tear volume, 
as its function is to clear debris and pathogens from the ocular surface [16]. Human tear volume is 
estimated to be approximately 7-9µL, meanwhile the cul-de-sac can temporarily encompass around 
30µL of an administered eye drop. The increase in the volume due to topical installation causes reflex 
blinking and rapid drainage from the ocular surface leading to a majority of the applied medication to be 
drained from the surface through the nasolacrimal duct within 15-30 seconds of installation [15]. 
Considering these precorneal factors, contact time with the adsorptive membranes of the ocular tissue is 
significantly lowered, resulting in less than 5% of the applied dose reaching the intraocular tissues [7]. 
 
Figure 2.1 Ocular anatomy and tissue barriers. Reprinted from [1]. 
The cornea, the anterior-most layer of the eye, acts as a mechanical barrier which limits the entry of 
foreign substances into the eye and protects the ocular tissues. It contains three main layers: the 
epithelium, stroma and endothelium. Each of these layers has a different polarity affecting the 
permeation of topically administered drugs. The corneal epithelium is lipoidal in nature which limits 
permeation of hydrophilic drug molecules. The stroma, unlike the epithelium, is highly hydrated and 
acts as a barrier to the permeation of hydrophobic drug molecules. The endothelium, the innermost layer 
to the cornea, separates the stroma from the aqueous humour and contains leaky junctions that facilitate 




anatomical characteristics of the cornea that produce significant barriers to drug absorption, the presence 
of drug metabolizing enzymes, such as esterases, peptidases, and proteases, present in the corneal 
epithelium, the outer-most layer of the cornea, significantly impacting drug bioavailability [15].  
The conjunctiva and the sclera play a critical role in the permeation of drugs that have poor 
corneal permeability. The conjunctiva contains tight junctions that are wider than those in the corneal 
epithelium, thus permitting hydrophilic molecules, however it is a highly vascular organ, thereby a 
significant source of drug loss into systemic circulation. The conjunctiva, similarly to the corneal 
epithelium, also contains drug metabolizing enzymes which limit drug bioavailability [18] .Finally, the 
sclera consists of collagen fibers and proteoglycans embedded in an extracellular matrix. The permeation 
of positively charged drugs is typically impacted as a result of binding to negatively charged 
proteoglycans [19].  
Next, drugs are exposed the choroid, a network of blood vessels supplying the retinal pigment 
epithelium (RPE). The RPE acts as the major barrier that limits the entry of protein drugs from the 
choroidal blood circulation [20]. The charge and charge density of the drug itself also plays a role in 
determining its transport across the capillary endothelium [21]. The blood aqueous barrier (BAB) 
present in the posterior segment is divided into inner and outer blood retinal barrier (BRB). The inner 
BRB is composed of tight junctions between retinal capillary endothelial cells and is anatomically 
similar to the blood-brain barrier (BBB). The outer BRB is formed by the tight junctions between RPE 
cells. The high density of tight junctions and pericytes render the inner BRB highly effective in limiting 
transport of drugs from the blood into the retina [22]. 
To date, most common ophthalmic drugs are administered topically in the form of eye drops on 
the corneal surface. Alternative delivery methods such as intravitreal or periocular injections have been 
developed to improve the bioavailability of the therapeutic agents, but due to the invasive nature of these 
methods, side effects such as retinal detachment or intravitreal hemorrhage have been observed [23]. As 
a result, topical application in the form of ophthalmic drops has been the method of choice for 
administered pharmaceutical agents for the treatment of infection affecting the anterior segment. This 
route has been extensively utilized, but is limited by the narrow lachrymal capacity and constant tear 
drainage. The challenges affiliated with these conventional methods of ocular drug delivery have lead 





2.3 Advantages of Nanoparticles for Ocular Drug Delivery 
At present, nanocarrier-based ocular drug delivery systems appear to be the most promising tool to meet 
the primary requirements of an ideal ocular delivery system. Nanocarriers, due to their small sizes, are 
likely to have high diffusivity across membranes such as the corneal epithelium: a significant number 
of studies have already demonstrated that the use of such nanomaterials via topical administration 
improved the corneal permeability of drugs [24], [25]. Similarly, due to their high surface-area-to-volume 
ratio, nanocarriers may also show improved interaction with the mucous membrane of the corneal surface 
to prolong the retention of the topically administered drug formulations.  
Biodegradable polymers have been thoroughly investigated for sustained hydrophilic drug 
delivery. These polymers degrade into non-toxic monomer by-products that are safely cleared from the 
eye and systemic circulation. Polyesters such as Poly(lactic-co-glycolic acid) (PLGA) and Poly(lactic 
acid) (PLA) are among the most common biodegradable polymers constituting micro/nanospheres. Their 
popularity stems from their biocompatibility, high encapsulation efficiency, sustained release, and ability 
to degrade into non-toxic by-products that are safely cleared from ocular tissues [12]. Other constructive 
materials include polyanhydrides [26] and cyclodextrins [27]. 






Figure 2.2 A schematic illustration of different nanomaterial-based ocular drug delivery systems. 
Reprinted and modified from [2]. 
Nanoparticles are generally composed of biodegradable polymers and lipids and include microparticles, 
liposomes, dendrimers, micelles, and nanowafers that are actively used as carriers for targeted delivery 
of hydrophilic drugs. Drug release from nanoparticles is dependent on physiochemical factors such as the 
rate of degradation of polymers and molecular mass. The surface charge of the nanoparticles also plays a 
crucial role in ocular penetration. One study demonstrated higher diffusion of anionic human serum 
albumin based nanoparticles in the vitreous relative to cationic particles [28]. Such negatively charged 
nanoparticles may be utilized to deliver positively charged drug molecules. 
Nanoparticles can be administered via various routes including topical, periocular, 
suprachoroidal and intravitreal. However, intravitreal injection often leads to clouding of the vitreous due 
to scattering of light by polymeric particles. While microparticles tend to sink to the lower part of the 
vitreal cavity attributed to their higher molecular mass. There are several examples of nanoparticle-
mediated ocular delivery systems for small molecules at pre-clinical and clinical stages, however only few 
for high molecular weight hydrophilic drugs like proteins and peptides. These are at early stages of 
development as demonstrated by successful delivery of IgG using anionic gold nanoparticles to the 
photoreceptor cells and the RPE by subretinal injection [29]. Development of core-shell nanoparticles for 
encapsulating both hydrophobic and hydrophilic cargo [30], PEGylation for prolonging nanoparticle 
circulation and enhancing tissue penetration, functionalization for stimuli-responsive targeting and 
delivery of nanoparticles in biocompatible gels are some of the future strategies for controlled long-term 
delivery of biotherapeutics [31]. 
 
2.4 Recent Developments of Nanomaterials for Hydrophilic Drug Delivery 
 
2.4.1 Microparticles 
In order to encapsulate water soluble drugs, microparticles are successful when prepared using the double 
emulsion method. Single emulsion microparticles are limited in their ability for hydrophilic drug delivery 
due to hydrophilic drugs partitioning into the aqueous phase of the emulsion, producing a burst release of 
the drug upon administration [32]. The double emulsion method is a simple one that allows researchers 
to control process parameters to efficiently encapsulate water soluble compounds. Poly(lactic-co-glycolic 
acid) (PLGA) is the most widely used biomaterial for microencapsulation and prolonged delivery of 




degradation products, lactic acid and glycolic acid, are taken up by our body’s citric acid cycle. The 
physicochemical properties of PLGA may be varied systematically by changing the ratio of lactic acid to 
glycolic acid which alters the release rate of microencapsulated therapeutic molecules. This is observed 
in a number of applications where PLGA microparticles prepared by the double emulsion method have 
shown varying release rates. In a study by Hachicha et al, the release of the vancomycin from PLGA 
microparticles in the first 24 h was around 90% [33].  Meanwhile, another study by Karal-Ylmaz et al. 
demonstrated the synthesis of PLGA microspheres for the controlled delivery of vascular endothelial 
growth factor, VEGF. They showed successful encapsulation and sustained release of biologically active 
VEGF molecules over a period of 28 days [34].  
During microparticle formulation using conventional solvent evaporation methods, an emulsifier 
is required to ensure droplet stability until the polymer concentration in the organic solvent is high enough 
to maintain particle conformation. The most widely used emulsifier in the preparation of PLGA 
micro/nanoparticles is poly(vinyl alcohol) (PVA) [35]. Feng et al showed that D-α-tocopheryl 
polyethylene glycol 1000 succinate (vitamin E TPGS; FDA-approved as a water-soluble vitamin E 
nutritional supplement) markedly improved drug loading from 0.3 mg/ml to 5mg/mL when PVA as used 
[36].  
The use of PLGA for drug delivery on the ocular surface carries unique challenges as the delivery 
of any therapeutic agent to the ocular surface will always be limited by tear clearance. Promising attempts 
have been made to overcome this hurdle with the development of mucoadhesive PLGA microparticles 
[37]. Chitosan, PEG, sodium alginate and poloxamers are examples of mucoadhesive polymers popularly 
used as a mucoadhesive coating in the formation of PLGA microparticles [38]. Chitosan-coated particles 
have shown mucoadhesion for up to 6 hours due to the positive surface charge which allows for their 
interaction with the negatively charged mucin chains on the ocular surface [37]. Though they offer many 
advantages, the obstacles hindering more widespread use of microparticle sustained-release formulations 
for clinical use include low drug loading, particularly of hydrophilic small molecules, high initial burst 
release and/or poor formulation stability [37]. 
 
2.4.2 Lipid-based Nanocarriers 
Lipid-based nanoacarriers have been extensively used as a colloidal system for controlled ocular drug 
delivery. These include liposomes, solid lipid nanoparticles (SLNs) and nanostructured lipid carriers 
(NLCs). Liposomes are lipid bilayer structures formed by self-assembly of amphiphilic molecules [39]. 




increased membrane permeability, and their ability to be metabolized in vivo [40]. The ability of 
liposomal systems to encapsulate both hydrophilic and lipophilic compounds enables a wide variety of 
drugs to be carried by these vesicles, including deoxyribonucleic acids (DNA), proteins, or imaging 
agents. When nucleic acids, molecules, or drugs are enclosed in a lipid-based coating, they have lower 
degradation rates than they would as free standing biopharmaceuticals because they are more readily 
taken up by cells via endocytosis [41]. The final organization, morphology, and physicochemical 
properties of lipid-based liposomes depends on the nature, size, and geometry of their lipid components, 
concentration, temperature, and surface charge [42]. 
Phospholipids are the most common amphiphile used for liposomal synthesis. Phospholipids are 
generally composed of one hydrophilic head and two hydrophobic tails. Depending on the composition 
of the phospholipids, liposomes can have positive, negative, or neutrally charged surfaces. When 
phospholipids are dispersed in water, they aggregate spontaneously into bilayers, which resemble the 
structures they form in biological membranes [42]. It has been concluded that cationic liposomes are more 
efficiently internalized by the corneal epithelium because they can interact more efficiently with 
negatively charged mucins at the ocular surface [43]. Generally, this positive charge of the liposomes has 
led to a greater corneal drug absorption by increasing drug residence time through ionic interactions [43], 
as well as an improved therapeutic effect [44]. In addition to the effect of the charge, the liposomal size 
has been reported to influence their interaction and transport across the cornea. Liposomes of sizes less 
than 100 nm generally exhibit significantly higher circulation times due to a decrease in opsonization of 
liposomes with blood serum proteins [4 5] . Though they offer many advantages, liposomes are typically 
unstable in biological media, and they are susceptible to phagocytic uptake and clearance. Encapsulation 
of biopharmaceuticals in liposomes is commonly achieved via a dehydration-rehydration method. 
Although this method yields high association efficiency without utilizing organic solvents and sonication 
(both factors that may cause drug denaturation), the high developmental cost and the instability of the 
particle size restricts its wide application.  
Bevacizumab (Avastin), a synthetic monoclonal antibody against VEGF, has shown beneficial 
effects on treatment of AMD [46], myopic CNV [47], glaucoma [48], and DR [49]. However, it has a 
short intravitreal half-life (3-5 days) and several injections are needed to achieve a therapeutic effect 
[47].  To avoid complications of intravitreal hemorrhaging, retinal detachments and cataracts [48], and to 
increase the half-life of bevacizumab, Abrishami et al.  encapsulated this protein into liposomes 
incorporated with cholesterol via the dehydration-rehydration method [50]. The results of this study 




comparison to free drug. Intravitreal injection of liposomes containing bevacizumab was well tolerated in 
rabbits through 42 days, providing a sufficient therapeutic concentration for neovascular eye diseases that 
was 5 times higher than free bevacizumab [50]. 
Solid lipid nanoparticles (SLN) are lipidic colloidal systems with an inner structure based on pure 
solid lipids. They are derived from oil-in-water (o/w) emulsions in which the liquid lipid is replaced with 
a solid lipid at room temperature. Several solid lipids such as stearic acid, triglycerides, carnauba wax, 
beeswax, cetyl alcohol, emulsifying wax, cholesterol butyrate, and cholesterol may be suitable for SLN 
preparation [1]. These solid lipids are typically biocompatible and offer various advantages including 
avoidance of organic solvents for formulation, improved physical stability and targetability, controlled 
release and easy scale-up [51]. However, low drug loading, burst-effect and rapid elimination by 
mononuclear phagocytic system (MPS) are some of the drawbacks of SLNs [52]. Due to their hydrophilic 
nature, most proteins are poorly encapsulated into the hydrophobic matrix of SLNs [53]. Some peptides 
such as cyclosporine A (CsA) are sufficiently hydrophobic to be encapsulated in the lipid core of SLNs. 
SLNs can be formulated by several methods such as high-pressure homogenization (hot and cold 
homogenization) [54], solvent injection [55], water in oil in water double emulsion (W/O/W) [56],  
high-shear homogenization [57], solvent emulsification evaporation and membrane contactor. W/O/W 
emulsions enhance the solubility of hydrophilic pharmaceuticals, allowing for delivery of hydrophilic 
macromolecules via SLNs [58]. Many studies evidenced that positively charged colloidal particles 
increase the penetration of drugs through mucosal barriers [59]. Chitosan (CS) is a cationic 
polysaccharide characterized by good mucoadhesive properties, penetration enhancement properties 
across various mucus epithelia and enzyme-inhibiting properties towards various proteolytic enzymes. 
Because the cornea and conjunctiva possess a negative charge [60], the administration of cationic 
particles has a positive impact on drug bioavailability. This is demonstrated by Bacsaran et al. who were 
able to incorporate CsA, commonly used to treat chronic dry eye syndrome, into cationic SLNs and 






Figure 2.3 Schematic representation of solid lipid nanoparticles (1) and nanostructured lipid 
nanocarriers (2) used in drug delivery. Imperfect NLCs are prepared by mixing solid lipids with 
small amounts of liquid lipids (oils) to prevent crystallization. Structureless NLCs’ lipid matrix is 
formed by a solid lipid that has an amorphous structure after solidification. Multiple NLCs are 
prepared using high amounts of liquid lipids blended with solid lipids. Reprinted and modified 
from [3]. 
Solid lipid nanoparticles have several advantages over other types of nanoparticulate systems as discussed 
earlier in this section. However, there are some limitations too, the most challenging being the degradation 
of active components during the production process which may be attributed to the stress and strain 
associated with the homogenization process. Biopharmaceuticals are sensitive to both physical and 
chemical stresses, and need gentle handling. The production of heat during processing may also cause 
drug degradation so the selection of a proper production method is vital [15]. 




water content of aqueous SLN dispersions. NLCs are composed of highly disordered solid and liquid 
lipids and can provide better drug protection and entrapment efficiency in comparison to SLNs [62], [63]. 
Shen et al. investigated the potentiality of CsA-loaded thiolated NLC as mucoadhesive delivery systems 
for topical ocular administration [64] and found that the addition of cysteine–polyethylene glycol stearate 
(a thiolated PEG derivative, which acts as a nonionic surfactant) on the NLC surface extended the 
precorneal retention time of the nanocarriers and improved the biodistribution of CsA in the conjunctiva. 
This achieving a satisfactory drug concentration within 24 h for an efficient immunomodulation [64].  
Both SLNs and NLCs have shown potential in delivering small molecules to ocular tissues [39]. 
Conversely, efficiency in delivering hydrophilic protein and peptide-based biopharmaceuticals to ocular 
tissues has not been fully exploited and requires further investigation. 
 
2.4.3 Dendrimers 
Dendrimers are monodisperse macromolecules that constitute branched, layered architectures composed 
of synthetic polymers that show promise as nanocarriers in several biomedical applications [4]. Some of 
the commonly used dendrimers are based on polyamidoamines, polyamines, polyamides (polypeptides), 
poly(aryl ethers), polyesters, carbohydrates and DNA. Among these, polyamidoamine (PAMAM) based 
dendrimers are most commonly used and commercially available. Unlike linear polymers, the 
multivalent property of dendrimers provides a means to achieve high concentrations of payloads 
including small-molecules, biopharmaceuticals and imaging agents [65]. 
The molecular weight and surface charge of dendrimers also play a crucial role in determining 
tissue accumulation profiles, drug release rates (from the polymer) and elimination rates. While, high 
molecular weights of dendrimers (N 40 kDa) prevent rapid clearance, uncharged or negatively charged 
surface limit nonspecific interactions [65]. In addition, numerous end groups offer a way to precisely 
control functionality with multiple copies of drugs, chromophores, peptides, proteins and multivalent 
ligand density. Such surface modifications can not only strengthen ligand-receptor binding and 






Figure 2.4 Schematic representation of drug encapsulated (a) and drug conjugated (b) dendrimers. 
Reprinted from [4]. 
PAMAM dendrimers as drug delivery vehicles for small molecules have shown improved biological 
response, tolerability and lower clearance from the ocular surface indicating their utility as an eye drop 
formulation [67]. PAMAM dendrimers showed remarkable interactions with membrane-associated 
mucin layers [67]. This is important because interactions between the nanoparticulate surface and tear film 
is one of the key factors for corneal permeation and increased residence time [66]. pH-dependent 
interactions of PAMAM dendrimers with ocular mucins were also investigated, suggesting stronger 
interactions at pathological conditions (pH 5.5 for tear fluid) compared to physiological conditions. A 
larger fraction of primary amine surface groups of PAMAM-NH2 dendrimers are protonated at low pH, 
resulting in a net-positive charge leading to an increased association with mucins. Research findings by 
Yao et al. reported increased permeation and retention time of cationic PAMAM dendrimer-puerarin 
complexes with increased bioavailability of puerarin in aqueous humor, further supporting the above data 
[68]. Other studies have also confirmed the delivery of biopharmaceuticals using different conjugation 
techniques with dendrimers. Tarallo et al. report the synthesis of a poly(amide)-based dendrimer 
functionalized at the termini with a membrane-interacting peptide derived from the herpes simplex virus 
(HSV) type 1 glycoprotein H (gH625–644). The peptidodendrimer inhibits both HSV-1 and HSV-2 at a 
very early stage of the entry process, preventing the virus from coming into close contact with cellular 
membranes, showing promising inhibitory activity towards viruses of the Herpesviridae family [69].  
 
2.4.4 Polymeric Micelles 
Polymeric micelles represent a class of nanocarriers that are composed of amphiphilic polymers which 
self-assemble in aqueous media to form organized supramolecular structures. Most of the polymeric 




block (hydrophilic-hydrophobic- hydrophilic) polymers, graft (hydrophilic-hydrophobic) and ionic 
(hydrophilic-ionic) copolymers such as Pluronics, polyesters, and poly(L-amino acids). For the majority 
of these systems, poly(ethylene glycol) (PEG) is the primary hydrophilic segment [70]. Micellar 
formation confides upon the reduction of the interfacial free energy [71]. The degree of self-aggregation 
generally depends on the polymer chain concentration, the properties of the drug or any targeting agents, 
and the mass and composition of the copolymer backbone [72]. Depending upon the molecular weight 
of the block copolymers, micelles can have different shapes including spherical, cylindrical and star- 
shaped structures [73]. Pepić et al. developed Pluronic F127 (F127) and CS cationic polyelectrolyte 
based micelles for dexamethasone (DEX). In vivo biodistribution studies in rabbits revealed an 
increase in bioavailability of DEX (AUC162.8 ± 11.23) in comparisons to commercial DEX (0.1% 
w/v eye drop (AUC67.5 ± 9.42) and F127 alone (AUC115.9 ± 8.31) which is attributed to the synergistic 
enhancement of transcorneal permeation caused by F127 and CH [74]. Liu et al. synthesized polymeric 
micelles using block-copolymer PLA-Dex surface functionalized with phenylboronic acid (PBA) for 
ocular delivery of CsA to treat dry-eye disease. PBA’s hydroxyl groups bind to SA through covalent 
diol-diol binding, allowing these polymeric micelles to stay on the mucus membrane and deliver drugs 
effectively over a longer period of time than commercial options [8]. The PBA modified NPs 
demonstrated encapsulation of Cyclosporine A (CsA), a dry eye treatment drug, and sustained release 
for up to 5 days in vitro, showing their potential as a long-term eye drop delivery platform. Gadad et al. 
prepared moxifloxacin loaded PLGA nanosuspensions, with entrapment efficiency up to 83.1%. These 
particles showed significantly higher permeation capability compared to commercially marketed 
eyedrops in ex vivo transcorneal permeation studies and also showed better antimicrobial efficacy 
compared to the marketed formulation [75].  
Polymeric micelles possess high biocompatibility, biodegradability, and multiplicity of 
functional groups. Their hydrophilic shell limits opsonin adsorption, which contributes towards a longer 
blood circulation time and evasion of scavenging by the MPS system. Nonetheless, they also suffer 
from low cellular uptake and tissue accumulation, instability upon dilution and limitations in entrapping 
hydrophilic drugs [1].  
 
2.4.5 Nanowafers 
Nanowafers are tiny transparent circular discs that are composed of various polymers including 




carboxymethyl cellulose (CMC). These are generally applied with a fingertip on the ocular surface 
and can withstand constant blinking without being displaced unlike topical eye drops. Nanowafers 
consist of arrays of drug-loaded nanoreservoirs which release drugs in a highly controlled manner 
ranging from a few hours to several days. The synergistic action between the polymers and the loaded 
drug leads to slow drug release thus enhancing drug residence time and subsequent absorption into 
ocular tissues [1].  
Yuan and group demonstrated the sustained release and enhanced corneal permeability of 
doxycycline-loaded PVA nanowafer over 24 h in mice [76]. The same group reported the efficacy of such 
PVA fabricated nanowafer loaded with axitinib for treating CNV in a murine ocular burn model 
demonstrating that once a day axitinib delivery by nanowafers was more efficacious than the twice a 
day topical eye drop treatment [76]. Importantly, at the end of stipulated drug release time, the nanowafer 
dissolves and fades away thus rendering ocular surfaces free of polymers [1]. 
 
Figure 2.5 Ocular drug delivery nanowafer: (A) Schematic of nanowafer instilled on the cornea. 
(B) Diffusion of drug molecules into the corneal tissue. (C) Nanowafer on a fingertip. (D)AFM 
image of a nanowafer demonstrating an array of 500nm diameter nanoreservoirs. Reprinted and 
modified from [1]. 
 
2.5 Conclusions/Future Perspectives 
The field hydrophilic ocular drug delivery has taken a significant stride forward with the advent of 
nanotechnology. Numerous recent studies have focused on using various types of natural or synthetic 
biodegradable polymers, such as chitosan, hyaluronic acid, PVP, PEO, PLA, PGA,  PLGA and etc., as 
building blocks for nanomaterials making them biocompatible and non-toxic. Popular nanomaterials for 
hydrophilic drug delivery, such as microparticles, lipid-based nanoparticles, dendrimers, polymeric 
micelles, and nanowafers as drug carriers, were proven to increase the ocular bioavailability of various 




sustained release of hydrophilic biopharmaceuticals which increased the duration of therapeutic activity, 
consequently reducing the need for frequent administration. Furthermore, these formulations did not 
affect the integrity or functionality of these therapeutics upon encapsulation. In the last decade, a great 
deal of research has focused on the controlled delivery of large hydrophilic compounds, such as protein 
and peptide drugs for various ocular indications like age related macular degeneration (AMD), choroidal 






Development of Double Emulsion Mucoadhesive Nanoparticles for 
Topical Ocular Drug Delivery 
	
3.1 Summary 
Mucoadhesive NP drug carriers have attracted substantial interest as a potential solution to the low 
bioavailability of topical formulations. In this study, NPs composed of a PLGA core and PLA-Dex-PBA 
shell were developed as mucoadhesive NP drug carriers (DE MNPs). The DE MNPs encapsulated up to 
85 wt% and exhibited sustained drug release for up to 7 days in vitro. Furthermore, DE MNPs show 
increase in DL% with increase initial wt%, but decrease in DL% with increase in MWt. These data show 
that DE MNPs have the potential for being a promising new ocular delivery system capable of 
encapsulating hydrophilic compounds and can be tuned to improve drug loading and release.  
 
3.2 Introduction  
Poly(lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible polymer, has the ability to 
degrade into non-toxic by-products (lactic acid and glycolic acid) that are metabolized by the human body. 
Encapsulation of drugs in PLGA based nanoparticles are popular because of the relatively slow rate of 
release of drugs over a prolonged period of time, allowing for less frequent administrations [77]. This is 
ideal because it increases patient compliance, reduces the discomfort of frequent administration to the 
eye, protects the therapeutic compound on the surface of the eye, and avoids peak-related side-effects 
[78].  
 So far, several formulations have been investigated to encapsulate hydrophilic drug substances, 
such as proteins and peptides, into a PLGA matrix using W/O/W double emulsion method. However, 
achieving functionalities such as passive targeting and active targeting using PLGA-based drug delivery 
systems is difficult because there is a deficiency of functional groups on the PLGA surface [77]. The 
conventional PLGA surface makes it challenging to achieve the cell affinity and immobilization of cell-
targeting molecules. Therefore, modifying the surface of a PLGA-based drug delivery system is essential 
especially in organs such as the eye where targeted drug delivery is important to the efficiency of the drug 
being delivered.    
 PLGA polymer chains and repeating units are mainly composed of ester groups whose activity is 




(COOH) termini was widely adopted, no obvious improvement in PLGA activity performance has been 
found [79]. Bifunctional poly(ethylene glycol) (PEG) (amine group (NH2)-PEG-NH2, MW of PEG 3–5 
kDa) has also been used as bio-linker between PLGA and active targeting molecule [80], involving 
multistep reactions. However, there is limited functional groups for the targeting molecule to attach on as 
one PLGA polymer chain can only get one reactive NH2 from the bio-linker bifunctional PEG. This 
greatly affects the properties of the PLGA surface and its reaction with other targeting molecules [77]. 
 The objective of this study was not to modify the surface of PLGA itself, but rather to modify the 
double emulsion method such that the second emulsion contained mucoadhesive properties. The double 
emulsion method was chosen because it retains the hydrophilic shell necessary for compatibility with the 
physiological environment in the eye at the surface, and also allows for encapsulation of hydrophilic 
compounds in the core. The first step in the double emulsion method consists of generating the first 
emulsion, a water-in-oil (W/O) emulsion, where the aqueous solution contains the hydrophilic active 
component, and the organic phase contains a polymer, such as PLGA, and a suitable surfactant with a low 
hydrophile-lipophile balance (HLB) typically between 4 and 6, such as SPAN80. The first emulsion is 
formed under high speed homogenization. The second emulsion, a water-in-oil-in-water (W/O/W) 
emulsion, typically consists of a hydrophilic surfactant with a higher HLB, typically between 8 and 18, in 
a larger aqueous volume that is also exerted under shear stress [81]. Here, PLGA and SPAN80 were used 
to generate the first emulsion, and PLA-Dex-PBA was used as the surfactant with a higher HLB (10.5) 
than SPAN80 (4.3) in the second emulsion.  
 The main drawbacks of the double emulsion method are the large sizes of the NPs, which have 
been documented to stimulate reflex tearing, and cause irritation and discomfort [82], and the leakage of 
the hydrophilic active components, responsible for low entrapment efficiencies [83]. Here, we consider 
polymer and surfactant ratios, polymer concentration, and polymer molecular weight based on previous 
work [84], [78], [85], [86] to generate a double emulsion mucoadhesive drug delivery carrier that is small 
in size and has high entrapment efficiencies of hydrophilic compounds. 
 
3.3 Experimental Section  
3.3.1 Materials 
Fluorescein-isothiocyanate dextran (MW 3kDa, 10 kDa, 40kDa), Poly(D,L – lactide-co-glycolide) (MW 
45 kDa – 75 kDa), SPAN80®, Dimethyl sulfoxide (DMSO), Dichloromethane (DCM), Dextran (MW: 10 
kDa), 3-Aminophenylboronic acid monohydrate (PBA), sodium periodate (NaIO4), glycerol, sodium 




(Canada). Acid-terminated PLA (MW: 20 kDa) was purchased from Lakeshore Biomaterials (USA) and 
washed with methanol to remove monomer impurities. TEM grids (F/C 400 mesh Cu) were purchased 
from Ted Pella (USA). Phosphotungstic acid was purchased from Fisher (Canada); uranyl acetate and 
lead citrate were borrowed. Simulated tear fluid (STF) was generated for the in vitro drug release 
experiments using a previously documented formulation [64].  
 
3.3.2 Synthesis  
Synthesis of a water-in-oil-in-water (W/O/W) emulsion first involved the formation of the primary 
emulsion (W/O). The primary emulsion was made by dissolving FITC-Dex (at desired concentration) in 
0.4mL of MilliQ and adding that to 2mL of 10mg/mL PLGA dissolved in DCM containing 5% w/v 
SPAN80. DCM and MilliQ are immiscible liquids that require ultrasonification to homogenize. Using 
the Fischer Scientific Branson Probe Sonicator, the mixture was sonicated for 30 seconds (pulse 0.2, 
amplitude 30) to obtain a primary water-in-oil emulsion [83].  
The primary emulsion was then added to a larger aqueous phase containing a surfactant in order to 
produce the secondary emulsion (W/O/W). The surfactant used in this phase was the amphiphilic block 
copolymer PLA-Dex-PBA which was prepared using a previously reported method [106]. In brief, PLA-
Dex-PBA was synthesized by dissolving PLA-Dex in DMSO (30 mg/ml), and added slowly into water 
under mild stirring. Oxidation of the dextran surface was carried out by adding 60mg of sodium periodate 
(NaIO4) and stirring for an hour. Subsequently, glycerol was added to quench the unreacted NaIO4. 
Surface functionalization with PBA was carried out using reductive amination in the presence of 
NaBH3CN for 24 hours. The mixture was then dialyzed in H2O for 24 hr to remove any unreacted solutes, 
changing the wash medium 4 times. All reactions were carried out in dark [106].  
To generate the second emulsion, PLA-Dex-PBA was dissolved in DMSO (12.5mg/mL) and added 
dropwise to 12.5 mL of MilliQ under vortex to generate a 0.1% w/v PLA-Dex-PBA solution. The 
primary emulsion was then immediately added to the 0.1% w/v PLA-Dex-PBA solution and 
homogenized using the Fischer Scientific Branson Probe Sonicator for 30 seconds (pulse 0.2, amplitude 
30) to obtain a water-in-oil-in-water emulsion. The mixture was left to evaporate the organic solvent 
overnight while under stirring (490rpm) then dialyzed in 1L of DI H2O the next morning using 12-14K 
molecular weight cut-off (MWCO) dialysis tubing for 1.5 hours to remove the DMSO. To make blank 






3.3.3 Characterization of PLA-Dex-PBA DE MNPs 
The mean particle diameter and polydispersity index (PDI) was determined using Dynamic Light 
Scattering (DLS) by measuring the Multimode-Size Distribution (MSD) volume-averaged mean 
diameters using a 90Plus Particle size Analyzer (Brookhaven, λ = 636 nm at 90°). The analysis was 
performed at room temperature, at a scattering angle of 90oC. DE MNPs were filtered through a syringe 
filter (pore size = 200nm) to remove the drug and NP aggregates, then diluted 20x prior to analysis. The 
zeta potential of the Control (no drug) DE MNP and the drug containing (encapsulated) DE MNP were 
measured using Zetasizer Nano ZS (Malvern Instruments Worcestershire, U.K.) using 200nm filtered 
sample. The sizes and morphology were further analyzed by Static Light Scattering (SLS). SLS 
measurements were processed in batch mode using a multi angle laser light scattering apparatus 
(Brookhaven BI-200SM Laser Light Scattering System) equipped with a 25mW Ga/As laser beam 
operating at λ = 636 nm. Light scattering intensities recorded at 5 angles between 45o and 155o were 
derived with the ASTRA software according to the Zimm procedure. The sensitivity of the SLS is greater 
than the DLS, thus the DE MNPs were further diluted 50x prior to analysis. Measurements of 
hydrodynamic radius (Rh) and radius of gyration (Rg) were obtained and used to assess DE MNP 
conformation. These findings were also confirmed using Transmission Electron Microscopy (TEM) 
equipment by drying the DE MNP suspension on 300 Mesh Formvar coated copper grids (Canemco 
and Marivac) and using phosphotungstic acid solution as the negative stain. TEM findings were further 
explored using a double staining method by drying the DE MNP suspension on 300 Mesh Formvar 
coated copper grids (Canemco and Marivac) and using lead citrate followed by uranyl acetate to stain 
the particles.  
 
3.3.4 FITC-Dex encapsulation 
The encapsulation of FITC-Dex in the DE MNPs was accomplished by dissolving the hydrophilic (model) 
drug in MilliQ for the aqueous phase in the primary emulsion. The DE MNPs, post dialysis, were filtered 
through a syringe filter (pore size 200nm) to remove the drug and NP aggregates. The NPs were subsequently 
filtered through Amicon filtration tubes (MWCO = 30 kDa, Millipore for 3kDa and 10kDa FITC-Dex loaded 
DE MNPs, MWCO = 100 kDa, Millipore for 40kDa FITC-Dex loaded DE MNPs) to further remove any 
remaining free drugs in the suspension. The filtered DE MNPs containing encapsulated FITC-Dex were re-
suspended and diluted in DMSO. The drug loading (wt%) in the polymer matrix was calculated by measuring 




Volume Spectrophotometer System (Biotek). The measurements were obtained in triplicate (n=3, mean ± 
S.D). The absorbance measured by the same procedure using DE MNPs without encapsulated drug was used 
as the baseline. The absorbance was correlated using a standard calibration curve of FITC-Dex in DMSO. 






Equation 1. Encapsulation efficiency 
 
DL% = EE	x	DL%-01231-4,+/ 
Equation 2. Drug Loading 
3.3.5 In vitro release  
Drug encapsulated NPs were prepared and filtered (pore size: 200nm) to remove non-encapsulated drug 
aggregates. A purified sample of NP-drug suspension was collected to measure the maximum absorbance 
and this was used as the 100% release point. Subsequently, 4mL of the NP-drug suspension was 
transferred to a dialysis membrane (MWCO = 100 kDa, Fisher Scientific) and dialyzed against 150 mL 
of simulated tear fluid (STF, pH 7.4) at 37 °C under mild stirring. At predetermined time intervals, 1 mL 
of the release medium was extracted and the same volume of fresh new STF was added to the release 
medium. The extracted release medium was used to perform UV-Vis absorption measurements at 492 
nm in triplicates (n = 3, mean ± S.E). The release medium was replaced at each time interval to maintain 
the concentration of FITC-Dex in the medium and to stay below the solubility limit of the FITC-Dex in 
STF. The release of free FITC-Dex was also obtained with identical procedure for comparative analysis. 
All experiments were performed in dark environment, and the beakers were sealed with Parafilm to 
prevent evaporation of PBS. 
 
3.4 Results & Discussion 
3.4.1 Size & Morphological Characterization 
Double emulsions are thermodynamically unstable but may become kinetically stable depending on their 
formulation and processing. Coalescence and Ostwald ripening are two important mechanisms that 
destabilize double emulsion droplets, and the diffusion through the organic phase of the hydrophilic active 




ripening process is generally modelled by the well-known Lifshitz-Slyozov-Wagner (LSW) theory, for 
O/W emulsions without excess of surfactant. This theory is based on the assumption that the diffusion of 
oil through water determines the overall Ostwald ripening rate of diffusion which may be accelerated by 
solubilization of oil in the aqueous phase [87]. Conversely, coalescence involves a diffusive transfer of 
the dispersed phase from smaller to larger droplets, causing fusion of droplets as a result of rupture of the 
thin film [87]. These factors can be overcome and the leakage effect reduced by using a high emulsifier 
concentration and a high polymer molecular weight. This would in turn increase the viscosity of the inner 
water phase.  
 Taking these limitations into consideration, we designed the DE MNPs to use high molecular 
weight PLGA (40-75kDa), and a high concentration of SPAN80 (5% w/v). SPAN80 was chosen because 
of its low HLB value and non-ionic nature, therefore improving solubilization characteristics such as non-
irritancy, and ability to prolong precorneal retention with enhanced permeability [88]. The concentration 
of 5% w/v was determined empirically as the minimum concentration of emulsifier required to prevent 
phase separation immediately after sonication to produce the first emulsion.  
Upon formation of DE MNPs using the solvent evaporation double emulsion method, their sizes 
and morphologies were characterized using light scattering techniques (DLS, SLS), and TEM 
respectively. FITC-Dex was used as the model drug to test the feasibility of DE MNPs a drug delivery 
system. Dynamic light scattering (DLS) was used to analyze the fluctuations in the intensity of scattering 
by droplets/particles due to Brownian motion [89]. Nanoemulsion droplet size, polydispersity, 
conformational shape and zeta potential were assessed using a particle size analyzer. These results are 





              Mean PDIb) 
         
           Rg/Rhc)     x Potential(d) 
     (mV) 
    Blank 
          DE MNPs 
167 ± 1 0.0583 ± 0.0301 1.01 ± 0.05 -58.5 ± 2.1 
FITC-Dex 
(10KDa;100wt%) 
161 ± 2 0.0747 ± 0.0252 1.19 ± 0.05 -61.3 ± 1.4 
Blank DE MNPs 
using PLA-Dex 
(n = 1) 
155 0.0937 0.970 -43.8 
Table 3.1 Characterization of blank and FITC-Dex loaded DE MNPs by (a) size, (b) polydispersity 




The sizes of DE MNPs were smaller than what was typically observed for double emulsions using PLGA 
in literature [85], [86], [90]. Small particle size is preferred for ocular drug delivery since larger particles 
have been documented to stimulate reflex tearing, and cause irritation and discomfort [82]. The sizes of 
blank DE MNPs (no drug) were comparable to those of FITC-Dex loaded (100wt%) DE MNPs (P > 0.05). 
Typically, the sizes of double emulsions are influenced by the polymer concentration [85], which were 
not significantly different (10KDa) between the control and FITC-Dex loaded samples. The small size 
produced by the double emulsion technique could be influenced by the stability of the primary emulsion. 
The more stable the primary emulsion, the smaller the particles [87].  
The polydispersity index (PDI) of DE MNPs describes the degree of homogeneity of the NP 
distribution [89]. Since laser diffraction was used for this analysis, a rough equivalent of particle 
polydispersity could be given by two factors/values namely, uniformity (how symmetrical the distribution 
is around the median point) and span (the width of the distribution) [89]. Both samples gave a 
polydispersity index below 0.10, indicating that the distribution consisted of a single size mode without 
any aggregates. This was aided by filtering DE MNPs with a 0.2um sized filter which eliminated any 
aggregates and ensured the solution consisted of a homogenous population of DE MNPs. We expected to 
see two distributions, one double emulsion, and one micelle because of the amphiphilic nature of PLA-
Dex-PBA. This was not evident in the PDI because the cumulant analysis can only determine the particle 
size distribution of a Gaussian distribution around mean particle size. For more bi- or polymodal particle 
size distributions, like we expected here, more complex analysis methods are required [91]. The two NP 
distributions were evident in the TEM images of DE MNP solutions (Figures 3.1 and 3.2).  
The morphology of blank DE MNPs was then examined and compared with FITC-Dex 
encapsulated in DE MNPs. The ratio of the gyration radius (Rg) to the hydrodynamic radius (Rh), Rg/Rh, 
is characteristic to the topology of the polymer. When the radius of gyration Rg from static light scattering 
and the hydrodynamic radius Rh from dynamic light scattering are found to be identical for each sample 
investigated (a ratio of 1.0), it is characteristic for spherical shells or vesicles [92]. Because PLA-Dex-
PBA is a surfactant, it can generate micelles in solution. The immediate addition of the primary emulsion 
to the PLA-Dex-PBA solution and immediate sonication is critical to the formation of vesicles because it 
interrupts micelle formation before the micelles become too stable. Waiting upwards of 10 minutes after 
creating the 0.1% w/v PLA-Dex-PBA solution before adding the primary emulsion and sonicating resulted 
in significantly larger DE MNPs (P < 0.05), with a higher PDI than was observed for DE MNPs after 
immediate addition, and an Rg/Rh ratio close to 1.7, which was characteristic of gaussian chains (Supp. 




The zeta potential is a key indicator of the stability of colloidal dispersions. The magnitude of the 
zeta potential indicates the degree of electrostatic repulsion between similarly charged particles that are 
adjacent in a colloidal dispersion. Nanoparticles with a zeta potential between -10 and +10 mV are 
considered neutral, while nanoparticles with zeta potentials of greater than +30 mV or less than -30 mV 
are considered strongly cationic and strongly anionic, respectively [93]. DE MNPs were characterized to 
be strongly anionic. Theoretically, highly positive or highly negative values of zeta potential indicate 
higher stability, according to the DLVO theory [93], but from a biological standpoint, particles having 
high positive or negative zeta potential value are prone to fast clearance from the body [93]. The highly 
negative charge of DE MNPs can be attributed to the PBA on the surface. The pKa of the PBA molecules 
are near 8.6 [162], thus at pH ~7.2 (the pH of DE MNPs), at which the measurements were taken, some 
percentage of the PBA molecules would be in their deprotonated state, contributing to the overall negative 
surface charges of the nanoparticles. The range of zeta potentials on nanoparticles with PBA molecules 
on the surface in literature is approximately -30mV [94]. This is an indication that there is something else 
contributing to the surface charge. In order to explore this further, DE MNPs were prepared using PLA-
Dex instead of PLA-Dex-PBA. Theoretically, the DE MNPs should form just as if PLA-Dex-PBA is being 
used, with a comparable diameter, conformation, and polydispersity which is observed. The zeta potential 
of the PLA-b-Dex NPs has been previously explored by the Frank Gu Research Group and found to be  
-2.63 ± 1.55 mV. The zeta potential of DE MNPs using PLA-Dex was significantly lower at -43.8 mV. 
Previous studies have shown that increase in polymer concentration or changing in the mixing mechanism 
does not change the zeta potential; however, changing the type and concentration of surfactants strongly 
affects the zeta potential [95]. This suggests that SPAN80 may be migrating to the outer surface of DE 
MNPs, thus contributing to the anionic charge observed.  
TEM confirmed spherical shell/vesicle structures and integrity of DE MNPs to retain their shape 
upon drug loading. The TEM images are shown in Figure 3.1. The sizes of the DE MNPs appeared smaller 
in the TEM images compared to the reading estimated by the DLS. Differences in particle size from light 
scattering techniques versus those seen by TEM can be attributed to 2 processes. It is possible that the 
NPs in solution have a tendency to aggregate, or that the drying process in preparing the TEM grids 
shrinks the NPs as a result of evaporation [96]. Since the polydispersity of DE MNPs is quite low (below 
0.1), and the DE MNPs are strongly anionic, significantly decreasing their tendency to aggregate, it is 
more likely that the difference in size seen between DLS and TEM is a result of the evaporation of water 





    
Figure 3.1 TEM images of blank DE MNPs (left: 100 nm scale bar) and FITC-Dex loaded DE 
MNPs (right: 100 nm scale bar) negatively stained with phosphotungstic acid. 
 
We expected the aqueous phases to appear darker than the oil phase. It is apparent that this is not observed 
in Figure 3.1. In order to assess whether the explanation for this was a result of lack of double emulsion 
formation or merely a result of the stain not being able to penetrate into the aqueous core, phosphotungstic 
acid was loaded into the core of DE MNPs during the synthesis process and reimaged showing some but 
not all particles exhibiting a dark interior and dark exterior (Supp. Figure 7.2). 
PLA-Dex-PBA block co-polymer will naturally self-assemble to form micelles in solution. In 
preparation of DE MNPs, this process was interrupted by the immediate addition of the primary emulsion 
to the solution containing 0.1% w/v PLA-Dex-PBA, and the immediate sonication to form the secondary 
emulsion. Because of this process, we expected to see a distribution of both micelles and double 





       
Figure 3.2 TEM images of blank DE MNPs (left: 100 nm scale bar) and FITC-Dex loaded DE 
MNPs (right: 100 nm scale bar) double stained with uranyl acetate and lead citrate. 
 
Using a double staining method using uranyl acetate and lead citrate [97], the morphology of blank DE 
MNPs was examined and compared with FITC-Dex encapsulated in DE MNPs. In theory this method 
should help distinguish between the micelles and the double emulsions. Small brighter (~50nm) particles 
are proposed to be micelles, meanwhile the larger darker particles with a distinctly darker ring around the 
edges are proposed to be vesicles. In making the stain, CO2 free water was required because lead stains 
are easily precipitated upon contact with CO2 [98]. The black precipitates seen in Figure 3.2 are a result 
of CO2 interacting with lead citrate. 
 
3.4.2 Drug Loading based on WT% 
FITC-Dex (10K) was encapsulated in the MNPs at three weight percentages: 10, 30, and 100%. The drug 
concentrations were explored to allow a better characterization of the DE MNPs’ drug loading abilities. 
Maximum encapsulation efficiency (EE%) of FITC-Dex was achieved at an initial feed of 30 wt% with 
an encapsulation efficiency of approximately 87%.  EE% did not change significantly when the initial 




indicating that more drug may be able to be incorporated into the formulation and higher drug percentages 
may be possible. This was also indicative that the PLGA-SPAN80 matrix that makes up the organic phase 
(the first emulsion) was viscous enough to decrease the diffusion rate of the drug from the inner aqueous 
phase to the external aqueous phase. This can be explained by the high molecular weight of PLGA (40-
75 KDa) and the concentration of SPAN80 (5% w/v) that stabilize the first emulsion. Samples were 
measured by DLS for their size, and UV-Vis for their encapsulation efficiency and drug loading. It was 
observed that drug loading does not significantly influence mean particle size, however this has been seen 
before [85], [99], [100]. Typically, the size of double emulsions are influenced by the polymer (PLGA) 
concentration, which was only 12.5% larger for the FITC-Dex loaded samples than the blank DE MNPs. 









    Blank DE MNPs 162 ± 5 0.0935 ± 0.0201    N/A    N/A 
           FITC-Dex (10wt%) 157 ± 1 0.0770 ± 0.0124          57.5 ± 14.3         5.75 ± 1.44 
     FITC-Dex (30wt%) 156 ± 1  0.111 ± 0.0461           86.0 ± 1.3          25.8 ± 0.4 
      FITC-Dex (90wt%) 170 ± 8 0.0690 ± 0.0278           87.3 ± 1.9          78.6 ± 1.7 
Table 3.2 Characterization of blank and FITC-Dex loaded DE MNPs at varying wt% by (a) size, 








3.4.3 Drug Loading based on MWt 
Keeping other conditions constant, the effect of FITC-Dex molecular weight on the properties of DE MNPs 
was evaluated (Table 3.3 and Figure 3.4).  Three different molecular weights, 3KDa, 10KDa, and 40KDa, 
were investigated for their drug loading abilities (initial 100 wt%). It remained true that the maximum 
encapsulation efficiency that can be achieved by DE MNPs is in the 80th percentile. No significant 
differences in particle size were observed for the 3KDa and 10KDa FITC-Dex samples (P > 0.05), however 
there was a significant increase in particle size for the 40KDa FITC-Dex sample. The sizes of double 
emulsions are influenced by the polymer concentration, which were not significantly different for the 3KDa 
FITC-Dex sample (3.75% increase), or for the 10KDa FITC-Dex sample (12.5% increase). However, the 
40KDa FITC-Dex sample (50% increase) changed the polymer concentration significantly and this was 
observed in the change in particle size. DL% were comparable for FITC-Dex(3K) and FITC-Dex(10K) (P 
> 0.05), however, the value decreased for FITC-Dex(40K) loaded DE MNPs (P < 0.05). This was likely 
due to the long dextran chain length of FITC-Dex(40K) allowing for the formation of diffusion channels 





     Mean PDIb)       EEc) 
       (%) 
       DLd) 
        (%) 
   Blank DE MNPs 154 ± 1   0.116 ± 0.0345 N/A N/A 
  FITC-Dex (3K) 147 ± 7   0.106 ± 0.0742 83.1 ± 3.27 83.1 ± 3.27 
 FITC-Dex (10K) 149 ± 4  0.0710 ± 0.0216 84.1 ± 2.38 84.1 ± 2.38 
  FITC-Dex (40K) 162 ± 1   0.917 ± 0.0472 60.7 ± 5.36 60.7 ± 5.36 
Table 3.3 Characterization of blank and FITC-Dex loaded DE MNPs at varying molecular weights 
by (a) size, (b) polydispersity index, (c) encapsulation efficiency, and (d) drug loading; n = 3 ±  s.e. 
 
 




3.4.4 In vitro release 
DE MNPs in STF at 37°C were analyzed by quantifying the FITC-Dex in the STF at predetermined time 
intervals using UV-Vis. DE MNPs showed total release at 168 hours, which is significantly longer than 
free-drug which showed total release at 24 hours (Figure 3.5). As seen in Figure 3.5, drug release from DE 
MNPs was slow and prolonged in comparison with FITC-Dex release from solution. The initial release 
after 0.5 hr from DE MNPs was 13.3% compared with the solution which released 31.2%. The release from 
solution increased and then plateaued at 12 hr with a cumulative release of 102.6%.  On the contrary, the 
DE MNPs showed increase in release until 168 hr (approximately 7 days).  
 
Figure 3.5 In vitro release of FITC-Dex from DE MNPs in STF (pH 7.4,  37 °C) over 12 days (left), 
over 48 hr (right); n = 3 ±  s.e 
 
There was an initial burst release of FITC-Dex, however this was 2.3x less than the initial release observed 
of the free-drug, suggesting that the DE MNPs retarded the release of FITC-Dex. A burst release occurs 
when more than 30% of the therapeutic agent contained by the drug delivery system is released from the 
drug delivery system within about 48 hours. Burst release can be a particular problem with water soluble 
drugs which have a propensity to quickly enter solution in an aqueous physiological environment [101]. 
We postulated that the mechanism of drug release occurs by a process of diffusion. The initial burst release 
can be explained by the presence of drug interacting with the surface of double emulsion nanoparticles [85], 
rather than/in addition to drug distributed in the internal matrix of the polymer.  
The rate of release of FITC-Dex in solution was consistent, however, the rate of release of FITC-
Dex from DE MNPs was faster in the first 12 hours (56.1%), and much slower in the remaining 156 hours 
releasing the remaining 10% of drug (for a total of 67.6%). This suggests that DE MNPs have drug both on 
their surface and in their core. It is possible that there was free-drug in the DE MNP solution, however, we 




initial slower rate further supports the probability of FITC-Dex associated with the surface of DE MNPs, 
which are released first. The small initial burst release is undesirable; release studies using DE MNPs 
containing only FITC-Dex encapsulated in the core should be conducted for comparison. 
 
The zeta potential, typically used to determine the surface charge of the particles, can be used to 





     PDIb) Rg/Rhc) x Potentiald) 
(mV) 
       DLe) 
        (%) 
Blank DE MNPs        163 0.0870 1.22 -59.2 N/A 
FITC-Dex loaded DE 
MNPs 
      160  0.112 1.21 -29.5 73.7 
Blank DE MNPs 
post-12 hr dialysis 
      163 0.0490 1.21 -60.2 N/A 
FITC-Dex loaded DE MNPs 
post-12 hr dialysis 
      154 0.0920 1.09 -62.9 15.7 
Table 3.4 Evaluation of presence of FITC-Dex in the core vs. on the surface of DE MNPs by (a) size, 
(b) polydispersity index, (c) conformation, (d) surface charge, and (e) drug loading; n = 1 
 
FITC-Dex loaded DE MNPs had a more positive zeta potential (P < 0.05) than blank DE MNPs, further 
supporting the hypothesis that some FITC-Dex was loaded on the surface of DE MNPs. Some of the FITC-
Dex loaded DE MNP sample was used for characterization of size, morphology, and drug loading (Table 
4.4), meanwhile the rest of the sample was subjected to dialysis for 12 hours (chosen based on release study) 
in an attempt to dissociate the FITC-Dex from the surface of DE MNPs. The blank DE MNPs and the FITC-
Dex loaded DE MNPs post-12 hr dialysis had comparable zeta potentials (P > 0.05), indicating that most, 
if not all, FITC-Dex on the surface of DE MNPs was removed. These particles were also characterized for 
size, morphology, and drug loading for comparison. ND DE MNPs had comparable effective diameters, 
vesicle morphologies and zeta potentials before and after dialysis (P > 0.05). FITC-Dex DE MNPs had 
comparable effective diameters and vesicle morphologies before and after dialysis (P > 0.05), however the 
drug loading and the zeta potential were significantly different (P < 0.05). By measurement of the zeta 
potential, it can be determined if the drug is shielded by the nanoparticle or not because if the drug is 
shielded, then the zeta potential will be close to the nanoparticle zeta potential [103]. The FITC-Dex loaded 
DE MNP sample had comparable zeta potential to blank DE MNPs post-dialysis (P > 0.05) suggesting that 




purpose of this thesis was not to study the effects of the process parameters on DE MNPs, however, this is 






Mucoadhesive abilities of DE MNPs 
	
4.1 Summary 
The mucoadhesive functionality on DE MNPs is PBA. The mucoadhesive binding occurs between the PBA 
grafts on the MNPs and N-Acetylneuraminic acid (sialic acid). Sialic acid (SA) is the terminal 
monosaccharide on the mucus membrane [104]. The binding is shown in Figure 4.1.   
 
 
Figure 4.1. PBA binding to SA 
 
PBA’s hydroxyl groups bind to SA through covalent diol-diol binding, allowing the MNPs to stay on the 
mucus membrane and deliver drugs effectively over a long period of time [105]. Fluorescence binding 
studies between SA and DE MNPs showed mucoadhesion in vitro, but when evaluated for ocular retention 
in vivo, DE MNPs failed to evade clearance; which may be attributed to their large size and/or strongly 
anionic surface charge.  
 
4.2 Introduction  
One of the biggest challenges of ocular drug delivery is the nature of the ocular anatomy. Topical 
administration is the most prevalent and popular method of drug administration, however, it is very difficult 
to achieve therapeutic drug concentrations because of precorneal factors such as blinking, nasolacrimal 
drainage, and transient residence time in the cul-de-sac [1]. To overcome these barriers, mucoadhesive 
nanoparticles have gained a lot of popularity, increasing contact time of the nanoparticles on the ocular 
surface, thereby increasing the bioavailability of the encapsulated drug.  
Chitosan, another biodegradable and biocompatible polymer has been investigated as a 
mucoadhesive functionality to decorate PLGA for more targeted binding. Chitosan functionalized PLGA, 
however, have been extensively used for cancer targeting or to improve oral bioavailability [106]. 




forms a complex with cis-diol groups of sugar residues, such that they are successful at interacting with 
sialic acids which are abundant on the mucin structures in the eye at physiological pH [107]. In addition, 
several studies have demonstrated biocompatibilities of PBA molecules using both in vitro and in vivo 
assays [108],[109],[110]. 
In a previous study, phenylboronic acid has been surface functionalized on PLA-b-Dex polymers 
[8]. The objective of this study was to develop a mucoadhesive nanoparticle delivery system for hydrophilic 
drugs that can reduce the administration frequency of ophthalmic drugs without compromising the 
therapeutic efficacy. Here, we investigated in vitro mucoadhesion as a proof of concept that PBA is on the 
surface of DE MNPs, and in vivo mucoadhesion for ocular retention after administration on rabbit eyes.  
 
4.3 Experimental Section  
4.3.1 Materials 
Fluorescein-isothiocyanate dextran (MW 10kDa), Poly(D,L – lactide-co-glycolide) (MW 45 kDa – 75 
kDa), SPAN80®, Dimethyl sulfoxide (DMSO), Dichloromethane (DCM), Dextran (MW: 10 kDa), 3-
Aminophenylboronic acid monohydrate (PBA), sodium periodate (NaIO4), glycerol, sodium 
cyanoborohydride (NaCNBH3), N-acetylneuraminic acid (SA) were purchased from Sigma Aldrich 
(Canada). Acid-terminated PLA (MW: 20 kDa) was purchased from Lakeshore Biomaterials (USA) and 
washed with methanol to remove monomer impurities.  
 
4.3.2 Synthesis  
Synthesis of a water-in-oil-in-water (W/O/W) emulsion first involved the formation of the primary 
emulsion (W/O). The primary emulsion was made by dissolving FITC-Dex (10mg/mL) in 0.4mL of 
MilliQ and that to 2mL of 10mg/mL PLGA dissolved in DCM containing 5% w/v SPAN80. DCM and 
MilliQ are immiscible liquids that require ultrasonification to homogenize. Using the Fischer Scientific 
Branson Probe Sonicator, the mixture was sonicated for 30 seconds (pulse 0.2, amplitude 30) to obtain a 
primary water-in-oil emulsion [83].  
The primary emulsion was then added to a larger aqueous phase containing a surfactant in order to produce 
the secondary emulsion (W/O/W). The surfactant used in this phase was the amphiphilic block copolymer 
PLA-Dex-PBA which was prepared using a previously reported method [106]. In brief, PLA-Dex-PBA 
was synthesized by dissolving PLA-Dex in DMSO (30 mg/ml), and added slowly into water under mild 
stirring. Oxidation of the dextran surface was carried out by adding 60mg of sodium periodate (NaIO4) and 
stirring for an hour. Subsequently, glycerol was added to quench the unreacted NaIO4. Surface 




24 hours. The mixture was then dialyzed in H2O for 24 hr to remove any unreacted solutes, changing the 
wash medium 4 times. All reactions were carried out in dark [106].  
To generate the second emulsion, PLA-Dex-PBA was dissolved in DMSO (12.5mg/mL) and added 
dropwise to 12.5 mL of MilliQ under vortex to generate a 0.1% w/v PLA-Dex-PBA solution. The primary 
emulsion was then immediately added to the 0.1% w/v PLA-Dex-PBA solution and homogenized using 
the Fischer Scientific Branson Probe Sonicator for 30 seconds (pulse 0.2, amplitude 30) to obtain a water-
in-oil-in-water emulsion. The mixture was left to evaporate the organic solvent overnight while under 
stirring (490rpm) then dialyzed in 1L of DI H2O the next morning using 12-14K molecular weight cut-off 
(MWCO) dialysis tubing for 1.5 hours to remove the DMSO. To make blank DE MNPs, the same process 
was followed, however 0.4mL of MilliQ was used to generate the first emulsion.  
 
4.3.3 Characterization of PLA-Dex-PBA DE MNPs 
The mean particle diameter and polydispersity index was determined using Dynamic Light Scattering 
(DLS) by measuring the Multimode-Size Distribution (MSD) volume-averaged mean diameters using a 
90Plus Particle size Analyzer (Brookhaven, λ = 636 nm at 90°). The analysis was performed at room 
temperature, at a scattering angle of 90oC. DE MNPs were filtered through a syringe filter (pore size = 
200nm) to remove the drug and NP aggregates, then diluted 20x prior to analysis. The zeta potential of the 
Control (no drug) DE MNP and the drug containing (encapsulated) DE MNP were measured using Zetasizer 
Nano ZS (Malvern Instruments Worcestershire, U.K.) using 200nm filtered sample. The sizes and 
morphology were further analyzed by Static Light Scattering (SLS). SLS measurements were processed in 
batch mode using a multi angle laser light scattering apparatus (Brookhaven BI-200SM Laser Light 
Scattering System) equipped with a 25mW Ga/As laser beam operating at λ = 636 nm. Light scattering 
intensities recorded at 5 angles between 45o and 155o were derived with the ASTRA software according to 
the Zimm procedure. The sensitivity of the SLS is greater than the DLS, thus the DE MNPs were further 
diluted 50x prior to analysis. Measurements of hydrodynamic radius (Rh) and radius of gyration (Rg) were 
obtained and used to assess DE MNP conformation.  
 
4.3.4 FITC-Dex encapsulation 
The encapsulation of FITC-Dex in the DE MNPs was accomplished by dissolving the hydrophilic (model) 
drug in MilliQ for the aqueous phase in the primary emulsion. The DE MNPs, post dialysis, were filtered 
through a syringe filter (pore size 200nm) to remove the drug and NP aggregates. The NPs were subsequently 
filtered through Amicon filtration tubes (MWCO = 30 kDa, Millipore for 3kDa and 10kDa FITC-Dex loaded 




remaining free drugs in the suspension. The filtered DE MNPs containing encapsulated FITC-Dex were re-
suspended and diluted in DMSO. The drug loading (wt%) in the polymer matrix was calculated by measuring 
the concentration of FITC-Dex in the solution by obtaining the absorbance at 518nm using Epoch Multi-
Volume Spectrophotometer System (Biotek). The measurements were obtained in triplicate (n=3, mean ± 
S.D). The absorbance measured by the same procedure using DE MNPs without encapsulated drug was used 
as the baseline. The absorbance was correlated using a standard calibration curve of FITC-Dex in DMSO. The 






Equation 1. Encapsulation efficiency 
 
DL% = EE	x	DL%-01231-4,+/ 
Equation 2. Drug Loading 
 
4.3.5 In vitro mucoadhesion via Fluorescence 
Fluorescence studies were conducted in order to evaluate the mucoadhesive properties of DE MNPs. This 
was done by determining the covalent interaction between the PBA grafts on the surface of DE MNPs and 
sialic acid (SA) molecules. The interaction of these two molecules quenches the intrinsic fluorescence of 
PBA, therefore, the interaction between PBA and SA can be quantified by analyzing the relative 
fluorescence intensities of DE MNPs in the presence of varying concentrations of SA. The relative 
fluorescence data can then be analyzed to determine the Stern-Volmer binding constant [110], KSV, using 
the Stern-Volmer equation as seen in Equation 3 below, 
 
I:
I = 1 +	K=>	x	
[Q] 
Equation 3. Stern-Volmer equation 
 
where I0 is the fluorescence intensity of the DE MNPs sample without SA ([SA] = 0 mM), I is the 
fluorescence intensity of DE MNPs with SA, and [Q] is the concentration of the quenching agent, SA. The 
KSV value is determined by calculating the slope of the linear fit.  
DE MNP suspensions were mixed with SA solutions to achieve a constant final concentration of 
DE MNPs (20 µg/ml) with varying SA concentrations (0, 10, 30, 60, 100, 150, and 200 mM). The samples 




relative fluorescence data was then analyzed to determine KSV using the Stern-Volmer equation. The 
mixtures were vortexed for 30 seconds before measurement, with the same parameters used. 
 
4.3.6 In vivo mucoadhesion via Ocular Retention 
All animal studies performed were in compliance with the guidelines of the Canadian Council on Animal 
Care (CCAC) and the University of Waterloo (UW) as well as regulations under the Animals for 
Research Act of Ontario Canada. Three male New Zealand White Albino rabbits (2.5 – 3.5 kg, Charles 
River Laboratories, Canada) were used for this study. FITC-Dex was encapsulated in the NPs and 
administered to rabbit eyes to track its ocular retention. At predetermined time intervals, images were taken 
using a confocal scanning laser ophthalmoscope (cSLO) of each of the rabbits’ eyes. 50µL of FITC-Dex 
encapsulated DE MNPs was administered in one eye, and 50µL of FITC-Dex (at the concentration which 
was encapsulated in the DE MNPs) was administered in the other for comparative analysis. All animals 
were acclimated in the animal facility for at least one week prior to the experiments. All formulations used 
in this study were dialyzed, filtered, and sterilized prior to administration to the animals. 
 
4.4 Results & Discussion 
4.4.1 Characterization and Drug Loading 
DE MNPs were synthesized for the purpose of mucoadhesion studies. Blank DE MNPs were used for in 
vitro fluorescence binding studies, meanwhile FITC-Dex loaded DE MNPs were used to evaluate in vivo 
mucoadhesion and ocular retention (Table 4.1). Sizes of blank DE MNPs and FITC-Dex loaded DE 
MNPs were comparable (P > 0.05), with similar Rg/Rh ratios and DL% observed during development 
studies discussed in Chapter 3.  
 
Formulation Mean Diametera) 
(nm) 
Mean PDIb)       Rg/Rhc)     DLd) 
     (%) 
Blank DE MNPs             150 ± 2 0.0957 ± 0.0875 1.21 ± 0.03      N/A 
FITC-Dex Loaded DE MNPs            152 ± 3 0.0980 ± 0.0649 1.02 ± 0.09 84.8 ± 1.1 
Table 4.1 Characterization of blank and FITC-Dex loaded DE MNPs by (a) size, (b) polydispersity 
index, (c) conformation, and (d) drug loading; n = 3 ±  s.e. 
 
4.4.2 In vitro mucoadhesion 
To quantitatively evaluate the mucoadhesive properties of DE MNPs, the covalent interaction between the 
PBA grafts on the surface of the MNPs and sialic acid (SA) molecules was studied using fluorescence 




molecules. Thus, the interaction between PBA and SA can be quantified by analysing the relative 
fluorescence intensities of MNPs in the presence of varying concentrations of SA. Blank DE MNPs were 
used for this study such that no other fluorescent moieties could skew the data.  
 
 
Figure 4.2 Fluorescence emission spectra and analysis DE MNP-SA binding. SA concentrations 
used past the saturation point skew results. Top left and right show the emission spectra and 
analysis with a wide range of SA concentrations, going past the saturation point, where large 
increases in SA do not significantly change the fluorescence. Bottom left and right show the 




The emission spectra (Figure 4.2, left) show decreasing fluorescence intensity with increasing SA 
concentrations as expected. I0/I vs [SA] was plotted for each SA concentration, and the data was fit to the 
Stern-Volmer equation through linear regression (Figure 4.2, right). This yielded a KSV value which is also 
known as a binding constant. The PBA-SA quenching occurs through photoinduced electron transfer, where 
the electron excited in the PBA is transferred to SA instead of being emitted. The type of fluorescence 
quenching that was being evaluated here is static quenching which yields a KSV equal to KA, the association 
constant. Dynamic quenching (when the quencher interferes with the excited state after formation) yields a 
KSV which is its own binding constant, similar but not equivalent to KA [110]. Static quenching allows us 
to make comparisons between the KSV value determined from this method and the literature sources of KA 
for PBA-SA binding [111], [112]. 
The analysis for KSV ends at the SA concentration after which the DE MNP solution becomes 
saturated with quencher (i.e. adding more quencher does not significantly change the fluorescence 
intensity). High concentrations cause a plateau to be formed in the analysis on the right; linear regression 
cannot be performed on this data. If concentrations of SA above the saturation point are used, linear 
regression is not accurate and the resulting KSV value is very different. However, looking at data below the 
saturation point, we see that the trend appears to be more linear and it is at these concentrations that we can 
obtain an accurate binding constant. Careful consideration must be taken to avoid using concentrations 
above the saturation point (which is usually noted qualitatively from the emission spectra and the graphical 
analysis), or else the reported data will be incorrect. Though disregarding the data points above the 
saturation point does give a more linear relationship, repeats of this study at lower concentrations (below 
saturation) should be conducted. We hypothesize that then, the KSV calculated from linear regression will 
be more precise and reflective of the binding between PBA and SA. 
Literature values place the KA for PBA-SA between 11.4 M-1 – 37.6 M-1 depending on the method 
used to determine it [113], [108], [114]. We expect the calculated KSV to be higher than this documented 
range as a result of the high number of PBA molecules decorating the surface of the DE MNPs. Previously 
reported KA values measuring PBA binding with sialic acid typically have one PBA moiety per compound 
[110], [108], whereas DE MNPs have a high number, 17.0 mol%, on the dextran monomer). This makes 
DE MNPs much more likely to bind to SA, as they have more binding sites available per NP. 
 
4.4.3 In vivo mucoadhesion 
The results in section 4.4.2 confirmed that it was possible to quantify the binding between DE MNPs and 
SA, alluding to PBA being the mucoadhesive component of DE MNPs, and to PBA likely being on the 
surface of DE MNPs. This prompted us to evaluate the mucoadhesive properties of DE MNPs in vivo. To 




Standardized images SLO (Figure 4.3) showed that the FITC-Dex delivered using DE MNPs demonstrated 
lower retention of FITC-Dex compared to the FITC-Dex control, which was especially noticeable at the 3 
hr time-point (Figure 4.3).   
 
Figure 4.3 Fluorescence images of NZW rabbit eyes treated with FITC-Dex and FITC-Dex loaded 
DE MNPs taken using confocal Scanning Laser Ophthalmoscopy (cSLO). 
 
Though DE MNPs show smaller particle sizes than what was typically observed for double emulsions using 
PLGA in literature [85], [86], [90], DE MNPs are significantly larger than PLA-Dex-PBA MNP micelles 
[8]. ICG delivered via PBA modified PLA-b-Dex micelles showed ocular retention beyond 24 hours on 
rabbit eyes, whereas free ICG was mostly cleared within the first 3 hours [105]. DE MNPs should 
hypothetically show similar ocular retention, but the fact that they did not may be attributed to particle size 
and surface charge. Larger NPs cause more irritation and discomfort than smaller NPs, stimulating reflex 
tearing and inducing a more rapid clearance [82].  Furthermore, the corneal surface contains negatively 
charged ocular mucin [115]. From the zeta potential data, it was learned that DE MNPs are strongly anionic, 
especially in comparison to their micelle counter-parts which showed zeta potentials close to 0 mV. This 
would cause the DE MNPs to be repelled by the negatively charged mucin and result in rapid clearance of 




explain the rapid clearance of DE MNPs from the ocular surface, despite the presence of PBA on the 
surface. Furthermore, it is possible that PBA is not doing its job as the mucoadhesive component of DE 
MNPs. High affinity SA-PBA complexation might not occur in a physiological environment, such as that 
of a rabbit’s eye, where most SA moieties are a-SA moieties [116]. Binding properties of SA to PBA arise 
from ester bond formation involving the a-carboxylate moieties of b-SA but not a-SA because the binding 
site responsible for high-affinity binding is blocked by a glycoside bond [116]. Therefore, though we think 
PBA is mucoadhesive, we are not sure that this property is retained in vivo. Further work needs to be done 




































Applications of DE MNPs in vitro 
 
5.1 Summary 
Mucoadhesive NP drug carriers have attracted substantial interest as a potential solution to the low 
bioavailability of topical formulations. In this study, NPs composed of a PLGA core and PLA-Dex-PBA 
shell were developed as mucoadhesive NP drug carriers (DE MNPs). The DE MNPs encapsulated 1% w/v 
active PVP-I and showed that this concentration is sufficient at eradicating a bacterial culture of Escherichia 
coli. Current formulations such as Betadine® use 5%w/v PVP-I for treatment of ocular infection due to 
rapid clearance [117]. These data show that the amount of PVP-I currently used in ocular formulations can 
be reduced and just as effective in application, should the mucoadhesive capabilities of DE MNPs in vivo 
be improved.  
 
5.2 Introduction 
Polyvinylpyrrolidone-Iodine (PVP-I) has gained a lot of popularity in the last decade due to its affordability 
and its very broad antimicrobial spectrum, including bacteria, viruses, and fungi. It has been used 
preoperatively and post-operatively in ocular surgery and shown efficacy in reducing bacterial colony 
formation [117]; it has also been shown to be effective on the cervix and vagina in gynecological cases 
[118]. Povidone-iodine interacts strongly to the double bonds of saturated fatty acids in the bacterial cell 
wall and cell organelle membranes and also oxidizes amino acids and nucleotides, causing pore formation 
in the lipid membrane [119].  
Povidone-iodine has found several applications in ophthalmology both in prevention of infections, 
and in the treatment of ongoing ocular infections. It has been employed preoperatively in an attempt to 
reduce the incidence of postoperative infections, such as endophthalmitis. PVP-I has also been popularly 
used as a topical antimicrobial agent effective in treating conjunctivitis and keratoconjunctivitis [118]. 
Furthermore, PVP-I has been used in the prevention of ophthalmia neonatorum, and as a means for 
decontamination of donor corneas [118].  
One of the biggest challenges of ocular drug delivery is the nature of the ocular anatomy. Topical 
administration is the most prevalent and popular method of drug administration, however, it is very difficult 
to achieve therapeutic drug concentrations because of precorneal factors such as blinking, nasolacrimal 
drainage, and transient residence time in the cul-de-sac [1]. It has been reported that 5% PVP-I drops are 
only suitable for use after a local anaesthetic, as instillation causes stinging and an acute red eye. 
Concentrations of 1% to 1.25% PVP-I cause transient stinging. If used for bacterial conjunctivitis, 




The objective of this study was to test the feasibility of DE MNPs to encapsulate PVP-I, a very 
effective antimicrobial agent used to treat bacterial and viral infections in the eye, and exhibit antimicrobial 
activity in vitro when released from DE MNPs. By encapsulating PVP-I we would be able to not only 
protect the drug from clearance, but also protect the eye from the stinging effects of PVP-I. Ideally, 
encapsulating a clinically relevant amount of PVP-I would minimize the stinging effect of the iodine on 
patients because PVP-I would be protected in biocompatible NPs, while still having a therapeutic effect. 
 
 
5.3 Experimental Section  
5.3.1 Materials 
Polyvinylpyrrolidone-Iodine (MW 40 kDa), Poly(D,L – lactide-co-glycolide) (MW 45 kDa – 75 kDa), 
SPAN80®, Dimethyl sulfoxide (DMSO), Dichloromethane (DCM), Dextran (MW: 10 kDa), 3-
Aminophenylboronic acid monohydrate (PBA), sodium periodate (NaIO4), glycerol, sodium 
cyanoborohydride (NaCNBH3), N-acetylneuraminic acid (SA) were purchased from Sigma Aldrich 
(Canada). Acid-terminated PLA (MW: 20 kDa) was purchased from Lakeshore Biomaterials (USA) and 
washed with methanol to remove monomer impurities. Escherichia coli (ATCC 10798) was purchased from 
Cedarlane Laboratories (CAN).  
 
5.3.2 Synthesis  
Synthesis of a water-in-oil-in-water (W/O/W) emulsion first involved the formation of the primary 
emulsion (W/O). The primary emulsion was made by dissolving PVP-I (10mg/mL) in 0.4mL MilliQ and 
adding that to 2mL of 10mg/mL PLGA dissolved in DCM containing 5% w/v SPAN80. DCM and MilliQ 
are immiscible liquids that require ultrasonification to homogenize. Using the Fischer Scientific Branson 
Probe Sonicator, the mixture was sonicated for 30 seconds (pulse 0.2, amplitude 30) to obtain a primary 
water-in-oil emulsion [83].  
The primary emulsion was then added to a larger aqueous phase containing a surfactant in order to produce 
the secondary emulsion (W/O/W). The surfactant used in this phase was the amphiphilic block copolymer 
PLA-Dex-PBA which was prepared using a previously reported method [106]. In brief, PLA-Dex-PBA 
was synthesized by dissolving PLA-Dex in DMSO (30 mg/ml), and added slowly into water under mild 
stirring. Oxidation of the dextran surface was carried out by adding 60mg of sodium periodate (NaIO4) and 
stirring for an hour. Subsequently, glycerol was added to quench the unreacted NaIO4. Surface 
functionalization with PBA was carried out using reductive amination in the presence of NaBH3CN for 




wash medium 4 times. All reactions were carried out in dark [106].  
To generate the second emulsion, PLA-Dex-PBA was dissolved in DMSO (12.5mg/mL) and added 
dropwise to 12.5 mL of MilliQ under vortex to generate a 0.1% w/v PLA-Dex-PBA solution. The primary 
emulsion was then immediately added to the 0.1% w/v PLA-Dex-PBA solution and homogenized using 
the Fischer Scientific Branson Probe Sonicator for 30 seconds (pulse 0.2, amplitude 30) to obtain a water-
in-oil-in-water emulsion. The mixture was left to evaporate the organic solvent overnight while under 
stirring (490rpm) then dialyzed in 1L of DI H2O the next morning using 12-14K molecular weight cut-off 
(MWCO) dialysis tubing for 1.5 hours to remove the DMSO. To make blank DE MNPs, the same process 
was followed, however 0.4mL of MilliQ was used in the generation of the first emulsion.  
 
5.3.3 Characterization of PLA-Dex-PBA DE MNPs 
The mean particle diameter and polydispersity index was determined using Dynamic Light Scattering 
(DLS) by measuring the Multimode-Size Distribution (MSD) volume-averaged mean diameters using a 
90Plus Particle size Analyzer (Brookhaven, λ = 636 nm at 90°). The analysis was performed at room 
temperature, at a scattering angle of 90oC. DE MNPs were filtered through a syringe filter (pore size = 
200nm) to remove the drug and NP aggregates, then diluted 20x prior to analysis. The zeta potential of the 
Control (no drug) DE MNP and the drug containing (encapsulated) DE MNP were measured using Zetasizer 
Nano ZS (Malvern Instruments Worcestershire, U.K.) using 200nm filtered sample. The sizes and 
morphology were further analyzed by Static Light Scattering (SLS). SLS measurements were processed in 
batch mode using a multi angle laser light scattering apparatus (Brookhaven BI-200SM Laser Light 
Scattering System) equipped with a 25mW Ga/As laser beam operating at λ = 636 nm. Light scattering 
intensities recorded at 5 angles between 45o and 155o were derived with the ASTRA software according to 
the Zimm procedure. The sensitivity of the SLS is greater than the DLS, thus the DE MNPs were further 
diluted 50x prior to analysis. Measurements of hydrodynamic radius (Rh) and radius of gyration (Rg) were 
obtained and used to assess DE MNP conformation. These findings were also confirmed using 
Transmission Electron Microscopy (TEM) equipment by drying the DE MNP suspension on 300 Mesh 
Formvar coated copper grids (Canemco and Marivac) and using phosphotungstic acid solution as the 
negative stain. TEM findings were further explored using a double staining method by drying the DE MNP 
suspension on 300 Mesh Formvar coated copper grids (Canemco and Marivac) and using lead citrate 





5.3.4 PVP-I encapsulation 
The encapsulation of PVP-I in the DE MNPs was accomplished by dissolving the hydrophilic drug in MilliQ 
for the aqueous phase in the primary emulsion. The DE MNPs, post dialysis, were filtered through a syringe 
filter (pore size 200nm) to remove the drug and NP aggregates. The NPs were subsequently filtered through 
Amicon filtration tubes (MWCO = 100 kDa, Millipore) to further remove any remaining free drugs in the 
suspension. The filtered DE MNPs containing encapsulated PVP-I were re-suspended and diluted in DMSO. 
The drug loading (wt%) in the polymer matrix was calculated by measuring the concentration of PVP-I in the 
solution by obtaining the absorbance at 288nm using Epoch Multi-Volume Spectrophotometer System 
(Biotek). The measurements were obtained in triplicate (n=3, mean ± S.D). The absorbance measured by the 
same procedure using DE MNPs without encapsulated drug was used as the baseline. The absorbance was 
correlated using a standard calibration curve of PVP-I in DMSO. The encapsulation efficiency (%) and drug 






Equation 1. Encapsulation efficiency 
 
DL% = EE	x	DL%-01231-4,+/ 
Equation 2. Drug Loading 
 
5.3.5 Bacterial assay 
Briefly, a trypticase soy agar plate was inoculated with bacterial strain E coli (ATCC 10798) under aseptic 
conditions and incubated at 37°C for 24 hours. After 24 hours, the colony agar was used to prepare a 
bacterial suspension with the turbidity of 1.0 McFarland (equal to 1.0×109 colony-forming units (CFU)/ml), 
by washing E coli with 0.85% saline (for 3 consecutive washes and centrifugations). Turbidity of the 
bacterial suspension was measured at 600 nm. This was further diluted to make two concentrations of E 
coli, one with 1.0×107 cfu/mL and one with 1.0×105 cfu/mL. 100µL of bacterial suspension was mixed with 
100µL of DE MNPs (0 hr – measured OD600) and incubated at 37°C for 6 hours (measured OD600). 25µL 
of this suspension was added to a trypticase soy agar plate and incubated at 37°C for 24 hours (measured 
OD600). Quantitative measurements were obtained via OD600 absorbance reading and qualitative 
measurements were obtained through observation of bacterial growth or lack thereof. 100µL bacterial 
suspension mixed with 100µL of MilliQ was used as the negative standard while 100µL bacterial 




in this study were dialyzed, filtered, and sterilized prior to inoculation with bacterial strain. All tests were 
performed in triplicate. 
 
5.4 Results and Discussion  
5.4.1 Characterization and Drug Loading 
In order to assess the application of DE MNPs, Polyvinylpyrrolidone-Iodine (also known as povidone-
iodine, PVP-I), was encapsulated and tested for in vitro anti-microbial activity. In PVP-I, 
polyvinylpyrrolidone is a polymer, similar to dextran, that is complexed by iodine such that a proton is 
fixed via a short hydrogen bond between 2 carbonyl groups of two pyrrolidone rings, and a triiodide anion 
is bound ionically to this cation [5] (figure 5.1). 
 
Figure 5.1 Chemical structure of polyvinylpyrrolidone-iodine (PVP-I). Reprinted from [5]. 
 
Polyvinylpyrrolidone, the hydrophilic polymer that acts as a carrier in povidone-iodine, does not have any 
intrinsic antibacterial activity, but by virtue of its affinity to cell membranes, it delivers diatomic free iodine 
(I2) directly to the bacterial cell surface [119]. Iodine’s targets are located in the bacterial cytoplasm and 
cytoplasmic membrane, and its killing action takes place in a matter of seconds. In contact with 
polyvinylpyrrolidone-iodine, sulfhydry1 compounds, peptides, proteins, enzymes, vitamin C, lipids, and 
cytosine are iodinated and oxidated by free iodine, resulting in inactivation of molecules that are essential 
for biologic viability [121]. PVP-I has gained a lot of popularity in the last decade due to its affordability 
and its very broad antimicrobial spectrum, including bacteria, viruses, and fungi. It has been used 
preoperatively and post-operatively in ocular surgery and shown efficacy in reducing bacterial colony 
formation [117]. 
 
Formulation Mean Diametera) 
(nm) 
          Mean PDIb)        Rg/Rhc)     DLd) 
     (%) 
Blank DE MNPs             167 ± 1  0.104 ± 0.0570 1.01 ± 0.05      N/A 
PVP-I Loaded DE MNPs            172 ± 1 0.0970 ± 0.0841 1.19 ± 0.05 7.55 ± 1.56 
Table 5.1 Characterization of blank and PVP-I loaded DE MNPs by (a) size, (b) polydispersity 





The PVP-I encapsulated DE MNPs were characterized for size, morphology and drug loading (Table 5.1). 
The sizes of PVP-I loaded DE MNPs were significantly larger (P < 0.05) from blank (no drug) DE MNPs. 
PVP-I has a molecular weight of 40KDa. This trend was also observed for FITC-Dex at the same 
molecular weight (40KDa) and can be attributed to the significant increase (50%) in polymer 
concentration. The morphology of blank DE MNPs was examined and compared with PVP-I encapsulated 
in DE MNPs. The ratio of the gyration radius (Rg) to the hydrodynamic radius (Rh) were found to be 
identical for each sample investigated (a ratio of 1.0), supporting the spherical shell/vesicle structure of 
the DE MNPs with and without drug loaded. Finally, the drug loading was examined and found to be quite 
low at 7.55 ± 1.56 % (42µg/mL of PVP-I = 1% w/v). The documented minimum inhibitor concentration 
(MIC) for PVP-I with E coli is 34mg/L [122]. This puts the concentration of PVP-I encapsulated in DE 
MNPs just above the MIC, promising bactericidal activity despite the low drug loading observed. This 
low drug loading is likely a result of the physical characteristics of PVP-I. Because of the nature of the 
structure of PVP-I, only the triiodide ion had fluorescent properties that allowed us to examine and 
quantify the amount of drug present in the DE MNPs. The triiodide ion is electrostatically bound to PVP 
by hydrogen bonding and therefore easily dissociates from PVP in solution. A free-drug dialysis test 
suggested that 43.8% of the triiodide ion gets dissociated in just 1.5 hr (Supp. Figure .3). The triiodide ion 
is the most important part of PVP-I because it’s the iodine that elicits the antimicrobial activity.   
 
5.4.2 Bacterial Assay 
We tested whether the amount of PVP-I (1% w/v) that was being encapsulated was significant enough to 
elicit bactericidal activity. Escherichia coli was used in this study at two concentrations: 1.0×107 cfu/mL 
and 1.0×105 cfu/mL. Bactericidal activity was monitored both qualitatively (visible growth or no growth 
on agar plates), and quantitatively via optical density at wavelength 600 (OD600). OD600 values can be used 
to measure turbidity which in turn is used to estimate the growth phase of the population (concentration of 
bacteria in the solution) [123]. The higher the concentration of bacteria in a liquid culture, the higher the 
optical density of that culture when measured. Theoretically, the OD600 should decrease upon bacterial cell 
death [123].  
Blank DE MNPs and DE MNPs loaded with PVP-I were the two experimental groups. PVP-I at 
the concentration loaded in the DE MNPs and Millipore H2O were the positive and negative controls, 
respectively. Statistical analysis shows that there was a significant decrease in the OD600 of the samples 
containing PVP-I loaded DE MNPs and PVP-I control (P < 0.0001), meanwhile there was no significant 
change in the samples containing blank DE MNPs or Millipore H2O (P > 0.05). Furthermore, the data 




and Blank DE MNPs (P < 0.05). These data are reported in Figure 5.1 (left). The DE MNP samples could 
not be directly compared to the controls because the addition of NPs increased the turbidity of the solution 
which directly affects the OD600, taken at 0 hr after DE MNP addition (as seen by the size discrepancy of 
the means between NPs and controls in Figure 5.1 (left)).  
 
 
Figure 5.1 OD600 of Treatments at 0hr and 24hr (left) and 95% confidence interval (right) of 
bactericidal effects of PVP-I loaded DE MNPs on Escherichia coli; n = 7 ±  s.e. 
 
The confidence interval shown in Figure 5.1 (right) indicates the range of the true mean is within 95%. 
The standard error of the mean tells us how narrow/wide the variance is, with the lack of overlap to include 
zero indicating statistically different population medians at the 5% level of significance. 
Bactericidal activity of PVP-I loaded DE MNPs suggests that 1% w/v of PVP-I is sufficient at 
eradicating a bacterial culture. Current formulations such as Betadine® use 5%w/v PVP-I for treatment of 
ocular infection due to rapid clearance [117]. Improving the mucoadhesion of DE MNPs in vivo insinuates 








Conclusions & Future Work 
 
6.1 Conclusions  
Research conducted in the Frank Gu Research Group suggests that NP drug carriers are capable 
of circumventing corneal clearance mechanisms by manipulating the surface functionalization of 
polymeric nanoparticles (NPs) such that they can interact with the ocular mucosa. In view of this 
background, this thesis was aimed at exploring the potential of mucoadhesive NPs (MNPs) to encapsulate 
hydrophilic drugs in the core of the NP, while maintaining mucoadhesive functionality in the shell of the 
NP. We developed a novel approach to formulate a double emulsion mucoadhesive nanoparticle (DE 
MNP) system to deliver hydrophilic molecules. 
Double emulsions allow us to generate a vesicle-like structure of hydrophilic interior and 
hydrophilic exterior and have been successful as nanoparticle drug carriers in the past. Most double 
emulsions utilize PLGA to make up the primary emulsion because it is a biodegradable and biocompatible 
polymer that has the ability to degrade into non-toxic by-products (lactic acid and glycolic acid) that are 
metabolized by the human body. The novelty in the DE MNP method involves using PLA-Dex-PBA in 
the outer emulsion, rather than common stabilizers such as PVA and Tween. The amphiphilic 
characteristics of PLA-Dex-PBA will arrange on the surface of PLGA emulsions with PLA facing the oil 
phase and Dex-PBA facing the exterior of the particle, making up the surface of DE MNPs. The PBA 
moieties on the surface of DE MNPs can covalently target the sialic acid moieties that are abundant on 
the ocular mucous membrane and avoid rapid clearance. DE MNPs form the foundation of the ocular 
drug delivery platform developed in this thesis, using fluorescein isothiocyanate dextran (FITC-Dex), a 
commercially used fluorescent dye, as the model drug to determine the capability of DE MNPs to 
encapsulate and release hydrophilic molecules. DE MNPs were first evaluated for size and morphology. 
They demonstrated sizes in the sub-200 nm range, nearly double the size of PLA-Dex-PBA MNP micelles. 
Their spherical shell/vesicle conformation was confirmed by static light scattering and TEM, and remained 
stable and unchanged with the addition of model FITC-Dex. DE MNPs demonstrated encapsulation of 
FITC-Dex up to 87 wt%, and sustained release for up to 7 days in vitro, showing their potential as a long-
term eye drop delivery platform. 
An in vitro mucoadhesion study as a proof of concept demonstration of PBA on DE MNPs’ 
surfaces was demonstrated by studying the binding kinetics of PBA to sialic acid through the Stern-
Volmer equation. The KA value for DE MNPs with sialic acid was determined to be 107.83 M-1, which 
was far higher than the literature values for PBA-SA. This gave confidence to the presence of PBA on the 




models. FITC-Dex was encapsulated in the NPs and administered to rabbit eyes to track its ocular 
retention. FITC-Dex delivered DE MNPs showed ocular retention for no longer than 3 hours on rabbit 
eyes; this trend was also seen for free FITC-Dex.  
Povidone-Iodine (PVP-I), an inexpensive and commercially available drug commonly used to 
treat ocular bacterial infections, was encapsulated and evaluated for bactericidal activity upon release from 
DE MNPs. DE MNPs revealed that that encapsulation of the drug did not change the properties of the 
drug, and also confirmed that the amount of drug being encapsulated (1% w/v) in DE MNPs, is a sufficient 
concentration to elicit antimicrobial activity, and better than current formulations such as Betadine® 
which uses 5%w/v PVP-I for treatment of ocular infection.  
This thesis demonstrated the development process of DE MNPs as topical ocular drug delivery 
systems for hydrophilic drugs. DE MNPs demonstrated delivery of a clinically relevant dosage of PVP-I, 
controlled release of therapeutics over prolonged period of time, and mucoadhesive properties in 
vitro. These DE mucoadhesive NPs show significant promise as a long-term topical ocular hydrophilic 
drug delivery system that significantly reduces the dose and the administration frequency of the eye drops 
while minimizing side effects.  
 
6.2 Recommendation for Future Work  
The research objectives outlined in section 1.2 were met through this body of work, and paved the way for 
future studies. The next step for assessing DE MNPs’ viability as mucoadhesive ocular delivery agents will 
be to further characterize the surface of these particles. Studying the surface of DE MNPs is critical for 
their success as mucoadhesive drug delivery agents. It is clear that PBA is on the surface of DE MNPs 
because its fluorescence is quenched in the presence of SA, however, mucoadhesion was not seen in vivo 
and this may be because of the large size and strongly anionic surface of DE MNPs. We hypothesize that 
this is due to SPAN80 migrating to the surface, however this is merely speculation. This data should be 
furthered with more replicates of the binding study, first, to see if a more linear relationship can be achieved, 
then, optimization of DE MNP process parameters. This would help determine the contributing factors to 
the anionic surface charge observed. Furthermore, in vivo studies should be repeated after the former steps 
are taken, to determine DE MNPs’ bioavailability on the ocular surface. Theoretically, DE MNPs should 
be able to avoid rapid clearance because of their mucoadhesive capabilities. Finally, in-depth analysis 
should be done on DE MNPs using a real drug rather than a model drug. Converting all the studies 
conducted using the model drug, using a hydrophilic antimicrobial agent that is easier to characterize than 
PVP-I, like ciprofloxacin, would conclusively reveal the potential of DE MNPs as hydrophilic ocular drug 
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    PDIb) 
 
Rg/Rhc) 
Blank DE MNPs 
(immediate addition) 
151     0.0480  0.916 
     Blank DE MNPs 
       (retarded addition) 
201      0.1270   1.73 
Table 7.1 Characterization of blank DE MNPs after immediate addition and retarded addition and 
sonication of primary emulsion to 0.1% w/v PLA-Dex-PBA by (a) size, (b) polydispersity index, and 




Figure 7.1 TEM of blank DE MNPs after retarded addition and sonication of primary emulsion to 







Figure 7.2 PTA loaded and stained DE MNPs 
 
 
Figure 7.3 Free-Drug Dialysis Test for PVP-I to test how much Iodine is lost when PVP-I is in solution. 
